| Entries |
| Document | Title | Date |
|---|
| 20100240574 | Heyl as a Therapeutic Target and a Diagnostic Marker for Neoplasia and Uses Therefor - The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia. | 09-23-2010 |
| 20100249015 | Use of VEGF in the Treatment of Retarded Fetal Growth in Pregnancy - An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF against may be a VEGF peptide or a gene construct encoding or expressing such a peptide. | 09-30-2010 |
| 20100267608 | MODIFICATIONS OF CUPREDOXIN DERIVED PEPTIDES AND METHODS OF USE THEREOF - The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells. | 10-21-2010 |
| 20100267609 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF - Compounds inhibit memapsin 2 β-secretase activity and selectively inhibit memapsin 2 β-secretase activity relative to memapsin 1 β-secretase activity. The compounds are employed in methods to inhibit memapsin 2 β-secretase activity, in the treatment of Alzheimer's disease, in the inhibition of hydrolysis of a β-secretase site of a β-amyloid precursor protein and to decrease β-amyloid protein in in vitro samples and in mammals. Proteins of memapsin 2 associated with compounds of the invention are crystallized. | 10-21-2010 |
| 20100267610 | Polypeptide comprising a knottin protein moiety - A polypeptide, with an amino acid sequence different from that of knottin protein, having a scaffold moiety with a helix moiety inserted in the scaffold moiety is described. The scaffold moiety comprises a knottin protein, or a fragment of knottin protein. | 10-21-2010 |
| 20100267611 | TREATMENT OF METABOLIC DISEASE - The invention relates to metabolic disease, including non alcoholic fatty liver disease, to risk factors associated with same and to phospholipid-containing compositions. | 10-21-2010 |
| 20100267612 | SUSTAINED RELEASE COMPOSITION CONTAINING SDF-1 - An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations. | 10-21-2010 |
| 20100267613 | HYPOALLERGENIC CEREAL PROTEIN AND USES THEREOF - A partial hydrolysate of cereal protein wherein the hydrolysate has a degree of hydrolysis between 9 and 18%, products containing such a partial hydrolysate and a method for the primary prevention of allergic reactions to cereal protein in a young mammal using such a partial hydrolysate are disclosed. | 10-21-2010 |
| 20100279918 | Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents - A construct comprising a cancer-homing peptide, an optional linker and a cell-penetrating peptide coupled to an anticancer drug and/or a diagnostic agent is disclosed. The homing peptide is for example a linear pentapeptide such as CREKA (SEQ ID NO:1), AREKA (SEQ 5 ID NO: 23) or CREKA0 (SEQ ID NO: 23), or a cyclic nonapeptide CPGPEGAGC (SEQ ID NO:2), and the cell-penetrating peptide is for example one of the peptides SEQ ID NO:3-SEQ ID NO:20. The anticancer drug may be selected from alkylating agents, antimetabolites and cytotoxic antibiotics, and the diagnostic agent may be a fluorescent label. Further, a method of delivering an anticancer drug and/or a diagnostic agent into a cancer cell 0 comprising administration of a construct according to the invention in vivo or in vitro is described. | 11-04-2010 |
| 20100279919 | COMPOSITIONS COMPRISING HUMAN INTEGRIN-LINKED KINASE-SIRNA AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that inhibit ILK expression. Methods of using the nucleic acid molecules are also provided. | 11-04-2010 |
| 20100279920 | CRITICAL CARE PRODUCT FOR NEONATAL CALVES - A product and method for treating dehydration in neonatal calves. The product is administered to dehydrated calves during treatment, to the exclusion of milk replacers or electrolytes. | 11-04-2010 |
| 20100286020 | MILK PROTEIN COMPOSITION AND USE THEREOF - A milk protein composition for use in treating or preventing chronic local inflammation in humans is disclosed. The invention also relates to the use of the milk protein composition for the manufacture of a nutritional composition and/or pharmaceutical composition for use in treating or preventing chronic local inflammation in humans. A nutritional composition, a pharmaceutical composition and a daily diet for treating or preventing chronic local inflammation in humans are also disclosed. | 11-11-2010 |
| 20100286021 | Methods of Modulating Prokineticin 2 for Treatment of Stress Response and Anxiety-Related Disorders - The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of anxiety-related disorders can be achieved by decreasing levels of PK2 and administering an effective amount of PK2 receptor antagonist. A method of modulating the behavioral response of a subject displaying symptoms of stress responses and/or anxiety-related disorders is disclosed. The disclosed methods indicate that PK2 is an essential regulator of behavioral stress response independent of HPA. | 11-11-2010 |
| 20100286022 | EDIBLE AND BIOCOMPATIBLE METAL-ORGANIC FRAMEWORKS - The disclosure relates generally to materials that comprise organic frameworks. The disclosure also relates to materials that are useful to store and separate biological agents that are environmentally friendly and biocompatible. | 11-11-2010 |
| 20100286023 | Compositions and Methods for Increasing Muscle Mass, Strength, and Functional Performance in the Elderly - Compositions and methods for increasing muscle mass, strength, and functional performance in the elderly by delivering a selection of amino acids, carnitine, and carboydrates with a low glycemic index. | 11-11-2010 |
| 20100292129 | Methods and Compositions for Enhancing Proteasome Activity - This invention relates to methods and compositions for enhancing proteasome activity in a cell. The methods and compositions for enhancing the activity of the proteasome in cells modulate the activity of Ubp6 (yeast) or Usp14 (human), an endogenous inhibitor of the proteasome. The methods and compositions partially or completely reduce the inhibitory activity of Usp14 on a proteasome, thereby specifically enhancing the protein-degradation activity of the proteasome. The invention also provides methods of screening to identify inhibitors of Ubp6, Usp14, and/or both Ubp6 and Usp14. | 11-18-2010 |
| 20100292130 | BIOLOGICAL ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY - The present invention relates to biologically active proteins comprising at least two domains wherein a first domain of said at least two domains comprises an amino acid sequence having and/or mediating said biological activity and a second domain of said at least two domains comprises an amino acid sequence consisting preferably of at least about 100 amino acid residues forming a random coil conformation whereby said random coil conformation mediates an increased in vivo and/or in vitro stability of said biologically active protein. Furthermore, nucleic acid molecules encoding the inventive biologically active proteins and vectors and cells comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions comprising the compounds of the invention as well as for specific uses of the biologically active proteins, nucleic acid molecules, vectors and cells of the invention. | 11-18-2010 |
| 20100298200 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 11-25-2010 |
| 20100298201 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES - The present invention provides biologically active peptidomimetic macrocycles with improved properties relative to their corresponding polypeptides. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 11-25-2010 |
| 20100298202 | BRI POLYPEPTIDES AND REDUCING AB AGGREGATION - This document relates to methods and materials for reducing Aβ aggregation. For example, methods and materials related to the use of BRI polypeptides (e.g., BRI2 polypeptides) and fragments of BRI polypeptides (e.g., a BRI23 polypeptide) to reduce Aβ aggregation in mammals are provided. | 11-25-2010 |
| 20100298203 | SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME - The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer. | 11-25-2010 |
| 20100298204 | FOOD MATERIAL FOR PROMOTING THE DIFFERENTIATION OF OSTEOBLAST AND INHIBITING THE DIFFERENTIATION OF OSTEOCLAST - Disclosed is an osteoblast differentiation promoting and osteoclast differentiation inhibiting agent which comprises a milk protein fraction having the following characteristics (1) to (4): (1) the milk protein fraction is derived from milk; (2) the milk protein fraction is a fraction containing a protein component having a molecular weight of 75,000 to 85,000 Daltons; (3) the milk protein fraction has a basic amino acid content of 13 to 15 wt % in the constitutional amino acid composition, and has a basic amino acid/acidic amino acid of 0.5 to 0.7; and (4) the milk protein fraction has an osteoblast differentiation promoting effect and an osteoclast differentiation inhibiting. | 11-25-2010 |
| 20100305022 | LOW MOLECULAR WEIGHT HEPARIN COMPOSITION AND USES THEREOF - Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided. | 12-02-2010 |
| 20100305023 | Method of Delaying The Onset of Clinically Definite Multiple Sclerosis - A method for delaying the onset of clinically definite multiple sclerosis in a patient at risk of developing clinically definite multiple sclerosis and retard long-term progression of multiple sclerosis and its symptoms, the method comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate to the patient, thereby delaying onset of clinically definite multiple sclerosis in the patient and retarding long-term progression of multiple sclerosis and its symptoms. | 12-02-2010 |
| 20100311639 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY - Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant. | 12-09-2010 |
| 20100311640 | SELF-ASSEMBLING PEPTIDE INCORPORATING MODIFICATIONS AND METHODS OF USE THEREOF - The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not self-assemble in isolated form. In certain embodiments of the invention the second amino acid domain comprises a biologically active peptide motif, e.g., a peptide motif found in a naturally occurring protein, or a target site for an interaction with a biomolecule. In certain embodiments of the invention the naturally occurring protein is a component of the extracellular matrix, e.g., a component of the basement membrane. The invention further provides scaffolds comprising the self-assembling peptides and methods of using the scaffolds including for cell culture, tissue engineering, and tissue repair. | 12-09-2010 |
| 20100317562 | Dietary Compositions - Compositions that include medical food emulsions are provided. The compositions can include a low pH solvent and amino acids wherein the amino acids are exclusive of at least one naturally occurring amino acid. Also provided are methods of making compositions that include medical food emulsions. Such medical food emulsions are useful in the nutritional support of individuals with inborn errors of protein metabolism. | 12-16-2010 |
| 20100317563 | METHODS FOR MODULATING THE PROLIFERATION AND DIFFERENTIATION POTENTIAL OF STEM CELLS AND PROGENITOR CELLS - Modulators of TRIM-NHL proteins and their use for modulating the proliferation and differentiation potential of stem cells and progenitor cells. Inhibitors of TRIM-NHL proteins, e.g. TRIM32, are useful for stem cell maintenance in vitro and in vivo. Assay methods for identifying TRIM-NHL protein modulators make use of the E3 ligase activity of TRIM32 or its interaction with Argonaute-1. | 12-16-2010 |
| 20100331232 | Starch-based hydrogel for biomedical applications - A starch-based hydrogel for the controlled delivery of a biologically active agent is described. The hydrogel comprises a dispersed phase, and a dispersion medium consisting substantially of water. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, or a combination thereof, or soluble starch. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents ranging from small molecule therapeutics to macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the hydrogel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host. | 12-30-2010 |
| 20100331233 | CRYSTAL OF XPA AND ERCC1 COMPLEX AND USES THEREOF - The present invention relates to complexes and crystals of an XPA peptide and an ERCC1 peptide, and structural coordinates of the complex obtained from such crystals. The coordinates are useful for identifying compounds that bind to ERCC1 and inhibit binding of XPA, and thus inhibitors of nucleotide excision repair (NER). The NER inhibitors are used for treating neoplastic diseases, cancer, and hyperproliferative disorders. | 12-30-2010 |
| 20100331234 | AMINOALCOHOL LIPIDOIDS AND USES THEREOF - Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings. | 12-30-2010 |
| 20100331235 | Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases - Histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject. In some embodiments, the histidine and/or a derivative thereof is used for the prevention and/or treatment of an inflammatory skin disease. | 12-30-2010 |
| 20110015116 | Method for treating muscular dystrophy - The object of the present invention is to provide a method for treating muscular dystrophy. The method for treating muscular dystrophy according to the present invention is characterized in comprising a step of administering a caldecrin. | 01-20-2011 |
| 20110021411 | REVERSE PROTEIN - A protein which is composed N-terminally of one or several C-terminal parts of the amino acid sequence of the mature tumour necrosis factor and C-terminally of one or several N-terminal parts of the amino acid sequence of the mature tumour necrosis factor, which activates epithelial ion channels and improves the lung function and which can be used for the manufacture of medicaments for the treatment of diseases associated with the lung function, such as oedemas. | 01-27-2011 |
| 20110021412 | Human Receptor Proteins; Related Reagents and Methods - Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 01-27-2011 |
| 20110028382 | TREATMENT OF ORAL PHARYNGEAL DYSPHAGIA - The invention provides compounds for use in a method of treating oral pharyngeal dysphagia in an individual and related products. One embodiment of the invention comprises administering to an individual an effective amount of a vanilloid receptor 1 (VR-1) agonist or high-affinity partial agonist to promote a swallow reflex. | 02-03-2011 |
| 20110028383 | Activated Forms Of Notch And Methods Based Thereon - The present invention is directed to methods for detecting or measuring Notch activation by observing or measuring the appearance of Notch on the cell surface or by observing or measuring Notch cleavage products that are indicative of Notch activation. The present invention is also directed to methods for detecting a molecule that modulates Notch activation by observing or measuring a change in the amount of Notch expressed on the cell surface or a change in the amount or pattern of Notch cleavage products. The present invention is also directed to a substantially purified activated heterodimeric form of Notch and components thereof and pharmaceutical compositions and kits thereof. The present invention is based, at least in part, on the discovery that Notch in its active form, i.e., the form that mediates signal transduction and that binds Notch ligands such as Delta, is a heterodimer of an about 180 kDa subunit (N | 02-03-2011 |
| 20110034368 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. Where the polyprotein contains immunoglobulin heavy and light chain segments or fragments capable of antigen recognition, in an embodiment a selectable stoichiometric ratio is at least two copies of a light chain segment per heavy chain segment, with the result that the production of properly folded and assembled functional antibody is made. Modified signal peptides, including such from immunoglobulin light chains, are described. | 02-10-2011 |
| 20110034369 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the human bitter-taste receptor hTAS2R7 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R7 bitter taste transduction or bitter taste response. | 02-10-2011 |
| 20110039757 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the human bitter-taste receptor hTAS2R3 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R3 bitter taste transduction or bitter taste response. | 02-17-2011 |
| 20110046038 | Polypeptide-Polymer Conjugates and Methods of Use Thereof - The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, cations, which are also provided. | 02-24-2011 |
| 20110053827 | INTRANASAL ADMINISTRATION - Intranasal administration of proteins, such as insulin and insulin analogues, in particular immunogenic proteins to the upper posterior region of a nasal cavity of a subject, and in particular the olfactory bulb region. | 03-03-2011 |
| 20110053828 | Use of Urea-Adjuvated Polypeptides for Diagnosis, Prophylaxis and Therapy - The invention relates to a method for infiltration of polypeptides in cells. The invention further relates to the use of the cells and urea-adjuvated polypeptides for the diagnosis, treatment or prevention of diseases. The invention further relates to the detection of polypeptide-specific immune cells. | 03-03-2011 |
| 20110065627 | Transdermal delivery of medicaments with combinations of cetylated fatty fatty ester penetrant complexes - This invention describes a topical delivery mechanism that contains a mixture of cetylated fatty esters that act as transdermal carriers of desired therapeutic molecules. The proposed cetyl fatty ester penetrant-complex (Base CFEP-complex) contains specific cetyl fatty esters, polar solvents, a carrier base (gel, cream, lotion, patch or stick gel), antioxidants and the desired pharmaceutical, cosmetic or antigenic response eliciting molecules that are efficaciously delivered by selectively varying component ratios in the complex. The invention proposes the use of transdermal delivery of medications such as those used in treatment of urinary incontinence, testosterone deficiency, arthritic and joint pain and other pains such as pain in the neck, lower back, back, knees, headaches, and other types of inflammatory pains, peripheral neuropathic pain, pain associated with repetitive strain injuries such as myofacial pain, rapid treatment of epileptic seizures, soluble antigens in the immuno-therapeutic treatment of allergies, actives in the treatment of foot cracks and elbow cracks, actives in the treatment of facial and other wrinkles in the form of anti-aging creams and gels and other topically delivered therapies. | 03-17-2011 |
| 20110065628 | Medication Combinations for the Treatment of Alcoholism and Drug Addiction - The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention provides compositions and methods for treating disorders using combinations of drugs such as topiramate, ondansetron, and naltrexone. | 03-17-2011 |
| 20110065629 | ENTERAL NUTRIENT - The present invention relates to an enteral nutrient for inflammatory bowel disease patients, including an active hexose correlated compound obtained by culturing mycelia of basidiomycetes. The enteral nutrient of the present invention is an enteral nutrient which is expected to exhibit an advantageous effect of AHCC on cancer patients and an action of alleviating inflammation in inflammatory bowel diseases, and to exhibit an action of inhibiting inflammation in patients who are suffering from ulcerative colitis or Crohn's disease and thus have difficulty with oral nutritional intake. | 03-17-2011 |
| 20110071071 | PSMB10: A DIAGNOSIS MARKER AND THERAPEUTIC TARGET OF CHRONIC REJECTION - The present invention relates to a method for diagnosing chronic graft rejection of a grafted organ in a subject from a biological sample of said subject, comprising: (a) determining in vitro an expression level value for PSMB10 in said subject biological sample, (b) comparing said value to at least one reference expression level value for PSMB10 in at least one reference sample, and (c) diagnosing if said subject is or not undergoing chronic rejection of said grafted organ. The invention also concerns a diagnostic kit or microarray for performing the method of the invention. The invention further concerns the medical use of proteasome inhibitors for treating chronic rejection. | 03-24-2011 |
| 20110077189 | COMPOSITION FOR STIMULATING NATURAL KILLER CELL ACTIVITY - The present invention relates to a nutritional composition comprising dietary fibre for stimulating natural killer cell activity, in particular in patients infected with HIV, oncology patients and elderly. | 03-31-2011 |
| 20110082070 | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency - The invention relates to a medicament which comprises a peptide extract of avocado and which can also comprise a composition containing D-mannoheptulose and/or perseitol, such as a water-soluble extract of avocado sugars, and/or a peptide extract of lupine. The inventive medicament is intended for the treatment and/or prevention of illnesses that are linked to an alteration in innate and/or acquired immunity, through an increase in the production of anti-microbial peptides, preferably hBD-2, without inducing inflammatory reactions, irritations or intolerances. | 04-07-2011 |
| 20110082071 | DELIVERY SYSTEM FOR AN ACTIVE INGREDIENT - The invention relates to a delivery system for an active ingredient. The system provides an encapsulating material for the active ingredient, wherein the encapsulating material is formed by combining a cationic component, an anionic component and the active ingredient. The anionic component is a mixture of carbonate and phosphate moieties, wherein the molar ratio of carbonate to phosphate moieties is from 9:1 to 1:9. | 04-07-2011 |
| 20110086794 | DELIVERY AGENT - A composition and method for delivering a peptide or protein into a cell. | 04-14-2011 |
| 20110092411 | RECOMBINANT LACTOFERRINS, METHODS OF PRODUCTION FROM PLANTS AND USES THEREOF - The invention concerns the use of a recombinant nucleotide sequence containing a DNAc coding for a lactoferrin, in particular human lactoferrin, or the derived proteins, and elements enabling a plant cell to produce lactoferrin or the derived proteins, coded by said DNAc, in particular a transcription promoter and terminator identified by the plant cell transcription machinery, to transform plant cells in order to obtain, from these cells, or plants obtained therefrom, lactoferrin or derived proteins. | 04-21-2011 |
| 20110092412 | METHOD OF PRODUCING TAT-HOXB4H - The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation. | 04-21-2011 |
| 20110105379 | SACCHARIDE-CONTAINING PROTEIN CONJUGATES AND USES THEREOF - Conjugates of a saccharide and a biomolecule, covalently linked therebetween via a non-hydrophobic linker and methods of preparing same are disclosed. Also disclosed are medical uses utilizing such conjugates. Glycosylation reagents for use in preparing these conjugates are also disclosed. Glycosylated proteins, characterized by improved performance, are also disclosed. | 05-05-2011 |
| 20110105380 | Protection of Nano-Scale Particles from Immune Cell Uptake - The present invention relates to a particle. The particle has a radius of less than about 1 μm, and includes at least one peptide comprising at least a biologically active portion of CD47. The present invention also includes a method of increasing the life of a particle in vivo in a mammal, the method comprising attaching at least one peptide comprising at least a biologically active portion of CD47 to a particle and administering the particle having CD47 so attached to a mammal, wherein the administered particle has a longer half life in the mammal than an otherwise identical particle that does not have CD47 attached thereto. | 05-05-2011 |
| 20110112010 | OCTANOIC ACID FORMULATIONS AND METHODS OF TREATMENT USING THE SAME - The invention features pharmaceutical formulations containing octanoic acid or a salt or ester thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors. | 05-12-2011 |
| 20110118171 | PROCESS FOR PRODUCING FATTY ACID AND ACTIVE INGREDIENT EXTRACTS, AND FATTY ACIDS AND ACTIVE INGREDIENTS THEMSELVES - A method for producing especially oleic acid and fatty acid extracts, and oleic acids and fatty acids themselves. In order to obtain active ingredients, especially oleic acids or fatty acids, from a noninvasive plant in large amounts, without the use of genetic manipulation processes, for reasons relating to agricultural laws, the oleic acid or fatty acid extracts are obtained from the biological material, i.e. the plant material, of the novel plant variety CANDY (CPVO 2007/1958). | 05-19-2011 |
| 20110130324 | METHODS FOR SYSTEMATIC CONTROL OF PROTEIN STABILITY - Methods and compositions to control the stability of proteins with special emphasis on antibodies and proteins with antibody-like structures, e.g., having an “immunoglobulin-like” fold, are described. Controlling the stability facilities different applications for a protein with the same function, but different stability. | 06-02-2011 |
| 20110130325 | Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same - Protein containing nanoparticles and methods of use thereof for the treatment of proliferative disorders are disclosed. | 06-02-2011 |
| 20110136722 | Drug Delivery Carrier - The present disclosure relates to a method for the sustained release of a drug, comprising the steps of: (a) preparing a biocompatible polymer having a hydrophobic group conjugated to the biocompatible polymer; and (b) contacting the biocompatible polymer to the drug for adsorbing the drug to the hydrophobic group of the biocompatible polymer, thereby obtaining a drug delivery carrier for the sustained release of the drug; wherein the drug is a protein, a peptide or a non-hydrophilic chemical drug; wherein when the drug adsorbed to the hydrophobic group of the biocompatible polymer is administered to a mammal, it shows a sustained release profile in the mammal. The drug delivery carrier according to the present disclosure having the hydrophobic group conjugated to the biocompatible polymer may be useful for adsorption of synthetic drugs having very low solubility in water. Further, it may regulate discharge rate of adsorbed drugs by regulating a portion of hydrophobic groups conjugated to the polymeric material. Thus, the present disclosure provides a broad-spectrum platform technology applicable to new hydrophobic synthetic drugs to be developed in the future as well as those that have been developed already but face difficulties due to low bioavailability. | 06-09-2011 |
| 20110136723 | NOVEL REAGENTS AND METHOD FOR CONJUGATING BIOLOGICAL MOLECULES - A compound of the general formula X-[Q-W—(CH═CH) | 06-09-2011 |
| 20110152166 | METHOD OF MODULATION OF PROTEIN PHOSPHORYLATION-DEPENDENT CONFORMATIONAL TRANSITIONS WITH LOW MOLECULAR WEIGHT COMPOUNDS - The present patent application discloses a method of identifying or validating a compound that modulates the phosphorylation-dependent activity of a target protein or protein complex, where the target protein or protein complex activity is regulated by phosphorylation, as well as the use of identified compounds for the production of a pharmaceutical preparation especially for the treatment of cancer, insulin resistance and diabetes. | 06-23-2011 |
| 20110152167 | BIODEGRADABLE BLOCK POLYMERS FOR DRUG DELIVERY, AND METHODS RELATED THERETO - A biodegradable block copolymer is disclosed, comprising a hydrophilic block derived from a polyether alcohol; and a hydrophobic block comprising a first repeat unit derived by ring opening polymerization of a first cyclic carbonyl monomer initiated by the polyether alcohol, the first repeat unit comprising a side chain moiety comprising a functional group selected from the group consisting of urea groups, a carboxylic acid groups, and mixtures thereof. No side chain of the hydrophobic block comprises a covalently bound biologically active material. The block copolymer self-assembles in water forming micelles suitable for sequestering a biologically active material by a non-covalent interaction, and the block copolymer is 60% biodegraded within 180 days in accordance with ASTM D6400. | 06-23-2011 |
| 20110152168 | ANTIADHESIVE CARBOHYDRATES - Provided is a pharmaceutical or dietetic product, which serves for reducing and/or blocking the adhesion of pathogenic substances and organisms to eucaryontic cells, in particular mammal cells. Said preparation contains at least one carbohydrate having an uronic acid unit on one of the ends thereof. 10 to 100% of the present, terminal uronic acid units pertaining to the carbohydrates are provided with a double bond that is especially situated between the C | 06-23-2011 |
| 20110160118 | METHODS AND COMPOSITIONS FOR TREATING ORAL AND ESOPHAGEAL LESIONS - The invention features methods and compositions for treating or preventing lesions of the upper alimentary canal, particularly oral aphthous or mucositis lesions. Trefoil peptides are administered in effective concentrations either alone or in combination with different therapeutic agents. | 06-30-2011 |
| 20110166058 | ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES - The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF. | 07-07-2011 |
| 20110166059 | MEANS AND METHODS FOR EVALUATING A THERAPY WITH A P38 MAP KINASE INHIBITOR - The present invention relates to a method for determining whether therapy with a p38 MAP kinase inhibitor is potentially beneficial or potentially contraindicated for a subject suffering from a p38-mediated condition comprising measuring in a sample obtained from the subject the presence of at least one chromatin remodelling gene and/or of at least one pro-inflammatory gene, wherein the treatment is potentially beneficial for the subject, if at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition; or wherein the treatment is potentially contraindicated for the subject, if at least one chromatin remodelling gene is overrepresented and/or at least one pro-inflammatory gene is underrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. The present invention also relates to medical uses and methods of treatment applying a p38 MAP kinase inhibitor for treating a p38-mediated condition in a subject, wherein the patient is amenable to the treatment with the p38 MAP kinase inhibitor, if in the subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. Furthermore, a packaged medicament and a kit are provided comprising a p38 MAP kinase inhibitor or means for determining the presence of at least one chromatin remodelling gene and/or at least one pro-inflammatory gene in a sample from a subject suffering from a p38-mediated condition and instructions for use indicating that a subject suffering from a p38-mediated condition is amenable to the treatment with the p38 MAP kinase inhibitor, if it has been determined whether in said subject at least one chromatin remodelling gene is underrepresented and/or at least one pro-inflammatory gene is overrepresented in comparison to a reference sample obtained from a subject not suffering from a p38-mediated condition. | 07-07-2011 |
| 20110172139 | PEPTIDES WHOSE UPTAKE BY CELLS IS CONTROLLABLE - A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases. | 07-14-2011 |
| 20110172140 | Poly-Pegylated Protease Inhibitors - Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods. | 07-14-2011 |
| 20110172141 | PROCESS FOR PREPARING MICROPARTICLES - A process for preparing microparticles comprising a biologically active material and a polymer and having a mean particle size expressed as the volume mean diameter (VMD) of from 10 to 500 μm, wherein the biologically active material is substantially insoluble in the polymer, which process comprises: a. contacting a mixture of the biologically active material or a precursor thereof, the polymer or a precursor thereof and a processing aid with a supercritical fluid which is capable of swelling the polymer under temperature and pressure conditions necessary to maintain the fluid in a supercritical state; b. allowing the supercritical fluid to penetrate and liquefy the polymer, whilst maintaining the temperature and pressure conditions so that the fluid is maintained in a supercritical state; c. releasing the pressure to precipitate microparticles comprising the biologically active agent and the polymer. | 07-14-2011 |
| 20110172142 | Functional Food Paste - Food compositions include carbohydrate, fat, and at least about 15 wt. % protein based on the total weight of the composition and a water activity of less than about 0.85 aw when measured at 25 degree celsius or a shelf-life at 25 degree celsius of at least 12 months. The food compositions are provided in a ready-to-eat form or incorporated into a bar, chew, filling or paste. | 07-14-2011 |
| 20110177996 | REGULATORY PROTEINS IN LUNG REPAIR AND TREATMENT OF LUNG DISEASE - The DNA-binding protein Sox17 has been found to play an important role in repair of pulmonary tissue after damage, disease, or injury. Nucleic acids encoding proteins involved in pulmonary repair, such as Sox17 and Spdef, can be used as a therapeutic composition for treating pulmonary disease. Methods of treatment of pulmonary injuries or pulmonary diseases are also disclosed, as are methods of identifying compounds effective in treating pulmonary injuries and diseases. | 07-21-2011 |
| 20110177997 | Cross-Beta Silk Genes - The present invention relates to silk proteins which can be used to produce silk with a cross-beta structure, as well as nucleic acids encoding such proteins. The present invention also relates to recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the production of personal care products, plastics, textiles, and biomedical products. | 07-21-2011 |
| 20110183884 | PAN-ANTIVIRAL PEPTIDES FOR PROTEIN KINASE INHIBITION - A method of inhibiting protein kinases by administering polypeptides derived from alpha-neurotoxin, and inhibiting protein kinases. Diseases treated thereby include cancer, influenza, Tourette's syndrome, pain, and neurological deficits. | 07-28-2011 |
| 20110183885 | NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77. | 07-28-2011 |
| 20110190193 | TREATMENT OF ENDOTHELIAL DYSFUNCTION IN DIABETIC PATIENTS - A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL). | 08-04-2011 |
| 20110195891 | FERMENTED MILK OR VEGETABLE PROTEINS COMPRISING RECEPTOR LIGAND AND USES THEREOF - The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal. | 08-11-2011 |
| 20110201539 | DETECTING SUCCINYLACETONE - This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry. | 08-18-2011 |
| 20110201540 | Glycosylation of Molecules - Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders. | 08-18-2011 |
| 20110201541 | TISSUE OCCLUDING AGENT - There is provided a bioabsorbable peptide tissue occluding agent that can be applied to large mammals including humans, the peptide tissue occluding agent being obtained by artificial synthesis to avoid concerns of infection by viruses and the like. | 08-18-2011 |
| 20110207653 | Microparticle Encapsulated Thiol-Containing Polypeptides Together with a Redox Reagent - The present invention relates to polymeric microparticles comprising a therapeutic polypeptide along with a redox reagent. Also disclosed are methods of using the microparticles, including methods of using the microparticles for delivery of the therapeutic polypeptide to a subject in need thereof. | 08-25-2011 |
| 20110207654 | PEPTIDE ANALOGUES - The present invention relates to compounds of Formula (I) | 08-25-2011 |
| 20110212881 | ALEURONE AS A PREBIOTIC FIBER FOR IMPROVED INTESTINAL HEALTH - The present invention is directed to methods of treating, maintaining or improving the feces quality and gastrointestinal tract health of mammals. The present invention is further directed to food products that can be used to treat, maintain or improve the feces quality and gastrointestinal tract health of mammals. In at least one aspect of the invention, the method includes introducing aleurone into the diet of a mammal. In another aspect the food product includes aleurone. | 09-01-2011 |
| 20110224128 | METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY - The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient. | 09-15-2011 |
| 20110230391 | FC GAMMA RECEPTOR FOR THE TREATMENT OF B CELL MEDIATED MULTIPLE SCLEROSIS - The invention relates to the Fcγ receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. The invention relates to pharmaceutical compositions containing the Fcγ receptor (Fc-gamma receptor) for use in treating multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis and/or an autoantibody driven form of multiple sclerosis. | 09-22-2011 |
| 20110230392 | NOVEL NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, AND NARC 25 MOLECULES AND USES THEREFOR - The invention provides isolated nucleic acids molecules and proteins, designated NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, and NARC 25, nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 09-22-2011 |
| 20110237492 | TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION - The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC. | 09-29-2011 |
| 20110245145 | METHODS AND REAGENTS FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INSULIN RESISTANCE - The present invention provides the use of βarrestin2 protein or its up-regulators for manufacturing a composition for the prevention or treatment of insulin resistance or related disease in mammals. The reagents and the kits for the specific identification of βarrestin2 protein or its coding gene or transcript are also provided which can be used in diagnosis of insulin resistance or related diseases. | 10-06-2011 |
| 20110257074 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION - Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the selected congener to be isolated, wherein said bi-phasic system has a partition coefficient from about 0.5 to 5.0; (c) subjecting the mixture dissolved in the bi-phasic solvent system to a counter current chromatography; and (d) isolating the selected congener in substantially pure form. | 10-20-2011 |
| 20110257075 | GUANIDINO ACETIC ACID USED AS AN ANIMAL FOOD ADDITIVE - The present invention relates to the use of guanidinoacetic acid and/or salts thereof as feed additive, in predominantly vegetarian diets, in particular use being made of salts with hydrochloric acid, hydrobromic acid and phosphoric acid. The use proceeds especially in individual doses from 0.01 to 100 g/kg of feed in the form of powders, granules, pastilles or capsules, the feed additive also being able to be used in combination with other physiologically active materials of value. The claimed use which is suitable especially for breeding and growing livestock, has recourse to a compound which is in particular stable in aqueous solution, can be converted to creatine under physiological conditions, and, in contrast to other guanidine derivatives, is completely available to physiological sectors of use. | 10-20-2011 |
| 20110263478 | SUR1 INHIBITORS FOR THERAPY - Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN). In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant. | 10-27-2011 |
| 20110263479 | Peptides - A peptide which can adopt a 3 | 10-27-2011 |
| 20110263480 | METHOD FOR TREATING PROSTATITIS UTILIZING MODIFIED PORE-FORMING PROTEIN PROAEROLYSIN - The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins. | 10-27-2011 |
| 20110263481 | Pharmaceutical Composition of Lyophilized Formulation and Preparation Method of the Same - Disclosed is a pharmaceutical composition of a lyophilized formulation including a multiblock copolymer in which two or more ABA-type triblocks are covalently connected through biodegradable dicarboxylic linkage, wherein A represents a polyethylene oxide block and B represents a polypropylene oxide block, a polybutylene oxide block, or a block of copolymer of propylene oxide and butylene oxide, the multiblock copolymer being included in an amount of 1 to 7 wt % based on the total weight of solution prior to the lyophilized formulation. The composition is capable of reducing reconstitution time of a lyophilized sustained-release formulation. | 10-27-2011 |
| 20110269665 | COMPOUND AND METHOD FOR TREATING MYOTONIC DYSTROPHY - Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1. | 11-03-2011 |
| 20110281786 | STEM CELL EXPANSION ENHANCING FACTOR AND METHOD OF USE - The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence having the activity of a peptide encoded by a Hoxb4 nucleotide sequence. Once delivered, the amino acid sequence is functionally active in the hematopoietic stem cell and enhances expansion thereof. The amino acid sequence may is a HOXB4 or HOXA4 protein. | 11-17-2011 |
| 20110288001 | BIOLOGICALLY ACTIVE PROTEINS ACTIVATABLE BY PEPTIDASE - The present invention provides biologically active proteins that are activatable by peptidase exposure, such as dipeptidase exposure. The biologically active protein may be a recombinant version of a protein factor that is processed from a native precursor molecule in vivo. Upon administration of the recombinant product to a patient in need, the proteins are converted to the active form in the body by endogenous dipeptidase. The design of such products simplifies the manufacturing process, and may provide for additional therapeutic benefits such as improved pharmacokinetics, half-life, and/or safety profile. The present invention further provides methods of treatment with such compounds, as well as methods of production and/or manufacture. | 11-24-2011 |
| 20110288002 | NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate | 11-24-2011 |
| 20110294717 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers - The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles. | 12-01-2011 |
| 20110301073 | Novel DNA-binding proteins and uses thereof - Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences. | 12-08-2011 |
| 20110301075 | Use of BBI/BBIC for Treatment of Muscular Atrophy and Degenerative Muscle Disease - Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided. | 12-08-2011 |
| 20110306539 | PROCESS FOR MAKING PARTICLES FOR DELIVERY OF DRUG NANOPARTICLES - A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing an excipient to at least one of the precipitant solution, the anti-solvent solution and the suspension of drug nanoparticles, the excipient being selected to maintain said drug nanoparticles in a dispersed state when in liquid form; and (c) drying the suspension of drug nanoparticles containing the excipient therein to remove solvent therefrom, wherein removal of the solvent causes the excipient to solidify and thereby form micro-sized matrix particles, each micro-sized particle being comprised of drug nanoparticles dispersed in a solid matrix of the excipient. | 12-15-2011 |
| 20110319315 | MUSCLE-BUILDING AGENT - A muscle-building agent comprising a whey protein hydrolyzate having a molecular weight distribution of 10 kDa or less, a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, and antigenicity equal to or less than 1/100,000th of that of β-lactoglobulin is provided. The whey protein hydrolyzate is very safe, exhibits high transparency when dissolved in water, has low bitterness, can be used for an arbitrary product, and exhibits a muscle-building effect. | 12-29-2011 |
| 20120004157 | HYDROXYPROLINE COMPOSITIONS AND USES THEREOF - The invention concerns novel use for Hydroxyproline in a pharmaceutical or dietary food or feed compositions for promoting growth e.g. of fish and/or for treating, ameliorating, or curing certain disorders including osteoporosis, psoriasis, enteritis and gingivitis. | 01-05-2012 |
| 20120004158 | Quaternised Ammonium Cyclodextrin Compounds - Use of a compound of formula (I): | 01-05-2012 |
| 20120015865 | NOVEL CLASS OF CATIONIC LIPIDS FOR TRANSPORTING ACTIVE AGENTS INTO CELLS - A subject of the present invention is the development of a novel family of cationic lipids and their use as vectors for in vitro, ex vivo and in 5 vivo delivery of biologically active agents. | 01-19-2012 |
| 20120021967 | SYNTHETIC ANTIBODIES - The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 01-26-2012 |
| 20120021968 | METHODS FOR TREATING OR PREVENTING UROLOGICAL INFLAMMATION - Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising
| 01-26-2012 |
| 20120021969 | PROSTHETIC IMPLANT SHELL - Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to the prostate of the patient, are provided. | 01-26-2012 |
| 20120028877 | Self-Buffering Protein Formulations - The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use. The invention in these and other respects can be productively applied to a wide variety of proteins and is particularly useful for making and using self-buffering formulations of pharmaceutical proteins for veterinary and medical use, especially, in particular, for the treatment of diseases in human subjects. | 02-02-2012 |
| 20120028878 | Membrane Evaporation for Generating Highly Concentrated Protein Therapeutics - The present invention relates to methods of generating highly concentrated protein solutions, e.g., an antibody solution, a therapeutic protein solution, etc. The methods of the invention include membrane evaporation, such as evaporation of protein-free solvent from the protein solution, which concentrates the protein. The methods of the present invention result in protein solution concentrations not previously achievable by conventional ultrafiltration methods, e.g., protein solution concentrations of greater than about 260 grams of protein per liter of solution. | 02-02-2012 |
| 20120028879 | HIGHLY SENSITIVE DETECTION METHOD FOR HIGHLY VIRULENT ORAL CAVITY BACTERIA - Provided is a method that involves the detection of protein antigen (PA) and/or collagen-binding protein (CBP) of oral cavity bacteria in a sample, and in which oral cavity bacteria that exacerbate hemolysis are detected for and/or subjects at high-risk for hemolysis aggravation are screened anchor the level of risk of the hemolysis aggravation in a subject is assessed if a PA is not detected anchor a CBP is detected in the sample. Also provided are a detection reagent and kit for use in the method. | 02-02-2012 |
| 20120035093 | Amphiphilic Polymer-Protein Conjugates and Methods of Use Thereof - Compositions and methods for transporting biologically active proteins and polypeptides, particularly across the blood-brain barrier, are provided. | 02-09-2012 |
| 20120040884 | Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration - Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm. | 02-16-2012 |
| 20120058931 | Drug target that promotes secretory granule-granule fusion - Munc18 proteins facilitate formation of SNARE complexes known to mediate membrane fusion. Much is known about the fusion of secretory granule (SG) to plasma membrane, mediated by Munc18a-SNARE complexes. It has been found that another Munc18 isoform, Munc18b, mediates SG-SG fusion which causes potentiation of secretion. The present invention has identified specific site mutations within Munc18b which further increased (called KR mutant) or reduced (called E59K mutant) SG-SG fusion compared to wild type (WT) Munc18b, causing amplification or reduction of insulin secretion, respectively. Compounds identified that mimic the actions of Munc18b-WT and Munc18b-KR mutant which increase SG-SG fusion, and those which mimic Munc18b-E59K mutant that block SG-SG fusion, are useful for treating and/or preventing diseases and/or conditions, whose underlying bases are a deficiency or excess of SG-SG fusion, respectively. These compounds also include conserved domains in Munc18a and Munc18c that mimic the KR and E59K sites in Munc18b. | 03-08-2012 |
| 20120058932 | ACTIVE INGREDIENT-PEPTIDE CONSTRUCT FOR EXTRACELLULAR CONCENTRATION - The present invention relates to an active ingredient-peptide construct for extracellular concentration, a process for the concentration of active ingredients in an extracellular space of a multicellular object, the use of the active ingredient-peptide construct according to the invention for the production of a medicinal product and a pharmaceutical composition containing the active ingredient-peptide construct according to the invention. | 03-08-2012 |
| 20120065122 | Pharmaceutical Composition and Method for Modulating Slow Myosin - The present invention directed to a method for modulating the expression level of slow myosin comprising administering to a subject in need thereof a therapeutically effective amount of nuclear receptor interaction protein (NRIP) modulator and calmodulin, and a pharmaceutically acceptable carrier. | 03-15-2012 |
| 20120065123 | Synthetic Antibodies - Methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 03-15-2012 |
| 20120065124 | CELL-PENETRATING PEPTIDES - A cell-penetrating peptide of (A) to (D) below gives cell membrane permeability and transmucosal absorbability to a physiologically active substance:
| 03-15-2012 |
| 20120071393 | Mutant CyaA Polypeptides and Polypeptide Derivatives Suitable for the Delivery of Immunogenic Molecules Into a Cell - The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. | 03-22-2012 |
| 20120077730 | Method for in Vitro Molecular Evolution of Protein Function - The invention provides a method for generating a polynucleotide sequence or population of sequences from parent polynucleotide sequences, the method comprising the steps of (a) providing a population of parent polynucleotide molecules, which population comprises plus and minus strands, (b) treating the population of parent polynucleotide molecules to generate a population of polynucleotide fragments thereof, (c) incubating the population of polynucleotide fragments under conditions which permit the formation of overlapping fragment pairs and (d) amplifying the overlapping fragment pairs using a polymerase to generate one or more product polynucleotide molecules which differ in sequence from the parent polynucleotide molecules, wherein step (d) is performed, at least in part, under conditions which favor the introduction of mutations into the one or more product polynucleotide molecules. | 03-29-2012 |
| 20120088713 | TNF INHIBITOR FORMULATION FOR USE IN IMPLANTABLE INFUSION DEVICES - A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37° C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature. | 04-12-2012 |
| 20120088714 | SYSTEM FOR STORAGE AND SUBSEQUENT HANDLING OF BOTULINUM TOXIN - A system and method for storage of botulinum toxin containing pharmaceutical compositions is herein disclosed. Particular aspects of the instant disclosure relate to vials having preferred internal geometries that provide optimized lyophilization, vacuum drying, storage, reconstitution and extraction of a botulinum toxin-containing pharmaceutical composition. | 04-12-2012 |
| 20120101021 | COMPOSITIONS, FORMULATIONS AND METHODS OF TREATING PREECLAMPSIA-TYPE DISORDERS OF PREGNANCY - This invention discloses a method of and composition for treating a PE-type disorder in a subject in need of such treatment comprising administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a TTR polypeptide in admixture with a pharmaceutically acceptable vehicle. | 04-26-2012 |
| 20120101022 | SELF-ASSEMBLING PEPTIDES BEARING ORGANIC ELECTRONIC FUNCTIONALITY AND APPLICATIONS EMPLOYING THE SAME - The aqueous self-assembly of oligopeptide-flanked π-conjugated molecules into discrete one-dimensional nanostructures is described. Unique to these molecules is the fact that the π-conjugated unit has been directly embedded within the peptide backbone by way of a synthetic amino acid with π-functionality that is compatible with standard Fmoc-based peptide synthesis or by way of a diacid or other bis(electrophile) that can covalently cross-link peptide chains presented on a synthesis support. The peptide-based molecular designs enforce intimate π-π communication within the aggregates after charge-screening and self-assembly, making these nanostructures attractive for optical or electronic applications in biological environments. In other embodiments, a convenient method to incorporate π-electron units into peptides that assemble into amyloid-like supramolecular polymers is disclosed. Self-assembly manipulates these “electronic peptides” into delocalized sub-10 nm one dimensional (1-D) nanostructures under completely aqueous conditions. | 04-26-2012 |
| 20120101023 | METHOD OF DIAGNOSING BLADDER CANCER - The present invention relates to a method of diagnosing cancer in a subject comprising detecting in the DNA of said subject at least one hypermethylated CpG island associated with said cancer, wherein an elevation in the level of methylation in said CpG island of said subject, relative to the level of methylation in said CpG island of a control subject, is indicative of said CpG island being hypermethylated. | 04-26-2012 |
| 20120101024 | Methods and Compositions for Differentiating Embryonic Stem Cells - Methods and compositions for differentiating mammalian stem and progenitor cells are provided. More particularly, methods and compositions for obtaining neural cells from human embryonic stem cells are provided. | 04-26-2012 |
| 20120108492 | LIGAND-SPECIFIC NON-ANTIBODY COMPOUNDS THAT INHIBIT CR2 ACTIVATION AND METHODS OF USE THEREOF - The present invention describes a novel non-antibody ligand-specific compound that selectively binds to a complement receptor type 2 (CR2) protein, a ligand thereof, or both, wherein the compound competitively inhibits CR2 ligand's binding to a CR2 protein in a standard assay. The present invention also describes compositions and methods of use thereof. | 05-03-2012 |
| 20120108493 | Polypeptide Fragments Comprising Endonuclease Activity and Their Use - The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds and pharmaceutical compositions comprising the identified compounds for the treatment of disease conditions due to viral infections caused by viruses of the Orthomyxoviridae family. | 05-03-2012 |
| 20120115771 | CARRIER - A pharmaceutical composition is provided comprising a vitamin E derivative, an anionic phopholipid-binding protein, an anionic phospholipid and a sterol. Also provided is a method for preparing a composition for delivering a cargo to a subject comprising a) forming liposomes from a vitamin E derivative, an anionic phospholipid-binding protein such as annexin, an anionic phospholipid such as phosphatidylserine and a sterol; and b) encapsulating the cargo in the liposomal composition. | 05-10-2012 |
| 20120115772 | CONJUGATION METHOD - A process for the conjugation of a polymer to a protein, which comprises reacting a polymeric conjugating agent with said protein, in an aqueous medium, in the presence of an amphipathic sugar polymer. The process is particularly useful when conjugating PEG to proteins, particularly to proteins which have previously proved difficult to PEGylate in acceptable yields, for example INF-β. | 05-10-2012 |
| 20120122759 | METHODS FOR REMOVING A CONTAMINANT USING INDIGENOUS PROTEIN DISPLACEMENT ION EXCHANGE MEMBRANE CHROMATOGRAPHY - Methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant are described, which methods comprise the sequential steps of: (a) passing the composition through an ion exchange membrane, where the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pI of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and the at least one contaminant, and (b) recovering the purified polypeptide from the effluent. | 05-17-2012 |
| 20120122760 | NOVEL LIPIDS FOR TRANSFECTION OF NUCLEIC ACIDS - Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions also are provided. | 05-17-2012 |
| 20120122761 | METHODS FOR DETECTING A POLYMORPHISM IN THE NFKB1 GENE PROMOTER - The present invention discloses a functional relationship between a recognized disease condition and a polymorphism in the nucleotide factor kappa B promoter (NFKB1). This relationship provides a platform for methods of altering promoter activity and for determining similar relationships between specific pathologies and identified polymorphisms. A statistically significant risk of developing ulcerative colitis was shown to be correlated with the presence of an ATTG insertion/deletion in the NFKB1 promoter and is likely to apply also to a variety of other inflammatory diseases. | 05-17-2012 |
| 20120122762 | 186 Human Secreted Proteins - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 05-17-2012 |
| 20120129757 | COMPOSITIONS AND METHODS FOR PROMOTING VASCULAR BARRIER FUNCTION AND TREATING PULONARY FIBROSIS - Active agents and compositions that promote barrier function or that inhibit permeability of the vascular endothelium associated with pulmonary inflammation are described. | 05-24-2012 |
| 20120129758 | MUSCLE FUNCTION ENHANCING PEPTIDE - The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition. | 05-24-2012 |
| 20120129759 | PROTEIN SURFACE REMODELING - Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to more hydrophilic residues (e.g., charged amino acids). Any number of residues on the surface may be changed to create a variant that is more soluble, resistant to aggregation, has a greater ability to re-fold, and/or is more stable under a variety of conditions. The invention also provides GFP, streptavidin, and GST variants with an increased theoretical net charge created by the inventive technology. Kits are also provided for carrying out such modifications on any protein of interest. | 05-24-2012 |
| 20120135912 | POLYPEPTIDE INHIBITORS OF VLA4 - The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods. | 05-31-2012 |
| 20120135913 | LYSINE COMPOUNDS AND THEIR USE IN SITE- AND CHEMOSELECTIVE MODIFICATION OF PEPTIDES AND PROTEINS - The present invention concerns new thiolysine and selenolysine compounds that can be used as building blocks for peptides and proteins, providing ligation handles for site- and chemoselective modification of said peptides and proteins. In particular, the invention provides. In particular, the invention provides (the use of) the compounds 5-thiolysine (also referred to as δ-thiolysine); 4-thiolysine (also referred to as γ-thiolysine); 5-selenolysine (also referred to as δ-selenolysine) and 4-selenolysine (also referred to as γ-selenolysine). The positioning of the thiol or selenol group at the respective carbon atom allows for a very efficient intramolecular transfer reaction to take place after conjugation with a selected ligand, and the thiol or selenol group may subsequently be removed using reported procedures, thereby restoring the native lysine structure, or be used as an additional conjugation handle. The methodology is fast and gives well-defined material. | 05-31-2012 |
| 20120142581 | Polymer Formulations for Delivery of Bioactive Materials - PLGA, PLA and PGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units. The polymers are particularly useful for drug delivery. | 06-07-2012 |
| 20120149630 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF - Poly(beta-amino esters) are end-modified to form materials useful in the medical as well as non-medical field. An amine-terminated poly(beta-amino ester) is reacted with an electrophile, or an acrylate-terminated poly(beta-amino ester) is reacted with a nucleophile. The inventive end-modified polymers may be used in any field where polymers have been found useful including the drug delivery arts. The end-modified polymers are particularly useful in delivery nucleic acids such as DNA or RNA. The invention also provides compositions including the inventive end-modified polymers, methods of preparing the inventive polymers, and method of using the inventive polymers. | 06-14-2012 |
| 20120165243 | USE OF DIETARY FIBRES AGAINST MUSCLE WASTING - A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units. | 06-28-2012 |
| 20120184480 | USE OF CONSTRAINED DIPEPTIDE AND TRIPEPTIDE MIMIC OLIGOMERS AS VECTORIZATION AGENTS - The invention relates to the use of oligomers having constrained dipeptide or tripeptide motifs as agents for the vectorization of active ingredients. | 07-19-2012 |
| 20120190609 | METHOD FOR PRODUCING A LIPID PARTICLE, THE LIPID PARTICLE ITSELF AND ITS USE - A method for producing a lipid particle comprising the following: i) providing a first solution comprising denatured apolipoprotein, ii) adding the first solution to a second solution comprising at least two lipids and a detergent but no apolipoprotein, and iii) removing the detergent from the solution obtained in ii) and thereby producing a lipid particle. | 07-26-2012 |
| 20120202732 | MODIFIED AAV CAPSID POLYPEPTIDES - The present invention is concerned with the provision of a polynucleotide encoding an AAV capsid polypeptide comprising an inserted peptide and a vector comprising said polynucleotide. Moreover, contemplated is a host cell comprising said polynucleotide or vector, a method for the manufacture of said capsid polypeptide as well as said polypeptide. Further included is an antibody specifically binding to said polypeptide and a medicament comprising said polynucleotide, vector, polypeptide, or antibody. Also contemplated are the use of said polynucleotide, vector, polypeptide, or antibody for the manufacture of a medicament for the treatment of vascular disease and a method for the identification of a compound binding to said polypeptide. | 08-09-2012 |
| 20120214728 | EX VIVO AND IN VIVO METHODS AND RELATED COMPOSITIONS FOR REGENERATING HEMATOPOIETIC STEM CELL POPULATIONS - Various embodiments provide methods and related compositions for increasing the population size of hematopoietic stem cells (HSCs) in patients that may benefit from reconstitution of stem cells and/or differentiated cells of the blood lineage. The present methods enable the production of HSCs ex vivo and in vivo by reducing latexin expression and/or latexin activity within HSC exposed to various antagonists. Inhibition of latexin expression and/or latexin activity by various antagonists can promote HSC proliferation and/or inhibit HSC apoptosis. Antagonists that can reduce latexin expression and/or latexin activity can be utilized to regenerate endogenous HSCs within patients affected with disorders, diseases, cancers, or therapies for such conditions, that result in the depletion or reduction in HSCs. | 08-23-2012 |
| 20120220517 | Glycopegylation Methods and Proteins/Peptides Produced by the Methods - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 08-30-2012 |
| 20120225807 | BACTERIAL MEMBRANE PROTEIN SECRETION - Improved bacterial secretion signals derived from pelB and ompA are provided. The improved variants enhance bacterial membrane secretion are thus useful for production of proteins secreted from bacteria including proteins displayed on filamentous phage particles, and, in particular, proteins requiring oxidative formation of covalent bonds, such as disulfide bonds within or between polypeptide chains in order to form a correctly folded and functional protein structure. Described herein are methods for the multivalent display of complex dimeric proteins on the surface of a bacteriophage particle and combinatorial synthetic libraries of such proteins displayed as a fusion polypeptide with filamentous phage pIX coat protein. Heterodimeric or more complex interchain bonded structures may also be displayed using the method of the invention. | 09-06-2012 |
| 20120231993 | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ALPHA-AMINO BORONIC ACID DERIVATIVES via SUBSTITUTED ALK-1-YNES - The present invention relates in general to the field of organic chemistry and in particular to the preparation of α-amino boronic acid derivatives. | 09-13-2012 |
| 20120238487 | POLYMER COMPOSITION USEFUL AS A PHARMACEUTICAL CARRIER - A polymer having a structure according to the following formula (I): wherein: A represents a hydrophilic group; B represents a hydrophobic aromatic group such as 5-dimethylamino-1-naphthalenesulfonyl (Dansyl), 9-fluorenylmethoxy carbonyl (Fmoc) and naphthalene (Naphth); D and E independently represent amine groups; F represents an amine group, the amine group being substituted with a B group and an A group, or the amine group being a quaternary ammonium moiety; wherein W, X, Y and Z each independently have values greater than or equal to (1), especially in the range of (1) to (10). | 09-20-2012 |
| 20120238488 | COMPOUNDS AND METHODS FOR TREATING NEOPLASIA - The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia. | 09-20-2012 |
| 20120238489 | METHOD FOR IMPROVING FUNCTIONAL PROPERTIES BY MEANS OF PULSED LIGHT, SAMPLES WITH IMPROVED FUNCTIONAL PROPERTIES AND USES THEREOF - Disclosed is a method for improving the functional properties of a sample, which comprises at least one component that can be modified upon absorbing ultraviolet light, the method including using pulsed light with an emission spectrum of 190-1100 nm and a high content of ultraviolet light to modify the component. The method makes it possible to obtain samples with improved functional properties (hydration, glass transition, solubility, water retention capacity, oil retention capacity, thickening, dispersing, emulsifying, foaming or gelling properties, film formation properties, bulking agent properties, surface properties (wettability, adhesion, etc.)) which are used in the food industry, the cosmetics industry, the pharmaceutical industry, the biomedical industry, the biotechnological industry, the chemical industry and in other industries. | 09-20-2012 |
| 20120245076 | COMPOSITIONS AND METHODS FOR DELIVERING RNAI USING APOE - This invention relates to the use of lipoproteins with oligonucleotides, both single and double stranded, and their use in delivering dsRNA for RNA interference. More specifically, the present invention relates to composititons containing oligonucleotides and alipoprotein E, which enables tissue-specific delivery and reduction of target expression. | 09-27-2012 |
| 20120245077 | PROKINETICIN 1 RECEPTOR - The present invention relates to methods of monitoring the biological activity of the PK1 receptor. | 09-27-2012 |
| 20120245078 | MEANS AND METHODS FOR TREATING ISCHEMIC CONDITIONS - The present invention relates to a combination of (a) at least one glucocorticoid; and (ba) at least one proteasome inhibitor and/or (bb) at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in the treatment or prevention of ischemic disorders of the central nervous system. Furthermore provided is at least one proteasome inhibitor and/or at least one nucleic acid encoding a glucocorticoid receptor, said glucocorticoid receptor being resistant to proteasomal degradation, for use in treating or preventing glucocorticoid resistance in ischemic disorders of the central nervous system. | 09-27-2012 |
| 20120252717 | CONJUGATES OF BIOLOGICALLY ACTIVE PROTEINS HAVING A MODIFIED IN VIVO HALF-LIFE - Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide. | 10-04-2012 |
| 20120252718 | Compositions and Methods for Regulating Cytochrome c-Mediated Apoptosis by tRNA - The invention relates to the discovery that tRNA is a potent regulator of cell survival, tRNA regulates the interaction between cytochrome c and Apaf-1 and subsequently Apaf-1 oligomerization into an apoptosome which in turn recruits and oligomerizes the caspase cascade which ultimately leads to cell death. Accordingly, the present invention provides compositions and methods for regulating cell survival. | 10-04-2012 |
| 20120264674 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS - The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 10-18-2012 |
| 20120264675 | CMV GENE PRODUCTS PROMOTE CANCER STEM CELL GROWTH - The disclosure relates generally to compositions and methods useful for inhibiting the infection and propagation of viral particles, particularly members of the Herpesviridae family, and more particularly to cytomegalovirus (CMV) and methods of treating diseases and disorders, including cell proliferative disorders, associated with CMV infection. | 10-18-2012 |
| 20120270766 | EARLY PROGRAMMING OF BRAIN FUNCTION THROUGH SOY PROTEIN FEEDING - Disclosed are methods for improving memory and/or cognition in an infant by administering soy protein to the infant's mother during pregnancy, and further administering soy protein to the infant after delivery. The soy protein may be administered to the infant's mother during lactation if the infant is breastfed and/or may be directly administered, for example, by administering the infant an infant and/or nutritional formula comprising soy protein. Also disclosed are compositions comprising soy protein that may be used in the methods. | 10-25-2012 |
| 20120295832 | Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds - The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery. | 11-22-2012 |
| 20120295833 | Polysaccharides having an adjustable degree of functionalization - An anionic polysaccharide comprising carboxylic acid functional groups of formula I: | 11-22-2012 |
| 20120302491 | MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR - This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERRγ activity to the subject. Such agents can include one or more ERRγ agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair). | 11-29-2012 |
| 20120302492 | Antibody Mimetic Scaffolds - Provided herein are protein scaffolds, e.g. antibody mimetic scaffolds, comprising a three finger protein domain that specifically bind to target molecules, polynucleotides encoding such proteins, methods of using such proteins, and libraries of such scaffolds. | 11-29-2012 |
| 20120309671 | PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use. | 12-06-2012 |
| 20120322717 | Compounds and assays for controlling Wnt activity - The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions. | 12-20-2012 |
| 20120322718 | Amygels in organic solvent for biomedical applications - A starch-based Amygel for the controlled delivery of a biologically active agent is described. The Amygel comprises a dispersed phase, and a dispersion medium consisting substantially of an organic solvent. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, soluble starch or a combination thereof. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents including small molecule therapeutics, macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the Amygel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host. | 12-20-2012 |
| 20120322719 | METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS - A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis. | 12-20-2012 |
| 20120322720 | STABLE NON-AQUEOUS SINGLE PHASE VISCOUS VEHICLES AND FORMULATIONS UTILIZING SUCH VEHICLES - This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10 | 12-20-2012 |
| 20130005642 | METHODS FOR RECOVERING PEPTIDES/AMINO ACIDS AND OIL/FAT FROM ONE OR MORE PROTEIN-CONTAINING RAW MATERIALS, AND PRODUCTS PRODUCED BY THE METHODS - According to a first aspect, hydrolysis of a protein-containing raw material and separation of amino acids/peptides is carried out, wherein the hydrolysis is effected by using the endogenous enzymes of the protein-containing raw material. The hydrolysate is passed through a membrane filter, wherein peptide/amino acids follow a permeate stream, whilst the active enzymes continuously break down any protein residues that are deposited on the membrane surface. The enzymes are passed together with retentate back to the hydrolysis. Furthermore, an amino acid and peptide product and an oil product are described and the use thereof is disclosed. | 01-03-2013 |
| 20130005643 | METHOD FOR PREPARING NANO-PARTICLES - The present invention relates to a method for preparing nano-particles, and more particularly, to a method for preparing nano-particles containing active materials in a simple and highly efficient manner through a grinding process. | 01-03-2013 |
| 20130023459 | Method for Preparing a Protein Emulsion - The present invention relates to a method for preparing a protein emulsion from bone material from which meat has been at least partially removed. The invention also relates to the protein emulsion obtained with such a method and to the use of this protein emulsion. In addition, the invention also relates to a food product comprising the protein emulsion according to the present invention. | 01-24-2013 |
| 20130023460 | AMPHIPHILIC LINEAR PEPTIDE/PEPTOID AND HYDROGEL COMPRISING THE SAME - The present invention provides an amphiphilic linear peptide and/or peptoid as well as a hydrogel that includes the amphiphilic linear peptide/peptoid. The amphiphilic linear peptide/peptoid is capable of forming a hydrogel. These peptides/peptoids include short amphiphilic sequences with a hydrophobic portion of aliphatic amino acids and at least one acidic, neutral, or basic polar amino acid. The amphiphilic linear peptide/peptoid is build up of non repetitive aliphatic amino acids, which may be in the L- or D-form. A plurality of such peptides/peptoids assembles to supramolecular helical fibers and forms peptide hydrogels after assembly. A corresponding hydrogel is formed in aqueous solutions at physiological pH and is thus useful for inter alia cell culture, tissue engineering, and drug release. Such hydrogels which are rigid, biocompatible and entrapping up to 99.9% of water are also well suited for applications utilizing electronic devices. | 01-24-2013 |
| 20130035279 | METHOD AND A SYSTEM FOR PRODUCING THERMOLABILE NANOPARTICLES WITH CONTROLLED PROPERTIES AND NANOPARTICLES MATRICES MADE THEREBY - This disclosure relates to a method and a system of producing nanoparticles and nanoparticle matrices of thermolabile, biocompatible matrix materials, like lipids and biopolymers with controlled properties. A prototype pulse-heat aerosol system is described for single-step production of free, thermolabile nanoparticles with sufficient control over size, morphology and crystallinity with controlled-release properties, for possible therapeutic, cosmetic or diagnostic use. Nanoparticles of the range 50 to 500 nm are obtained and are found suitable for controlled drugs delivery. | 02-07-2013 |
| 20130045914 | BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 02-21-2013 |
| 20130059768 | LIPID COMPOSITIONS WITH HIGH DHA CONTENT - The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like. | 03-07-2013 |
| 20130059769 | TOPICALLY ADMINISTERED, SKIN-PENETRATING GLYCOSAMINOGLYCAN FORMULATIONS SUITABLE FOR USE IN COSMETIC AND PHARMACEUTICAL APPLICATIONS - The present invention relates to topical glycosaminoglycan compositions, particularly hyaluronan compositions, that facilitate the penetration of modified glycosaminoglycans through the skin barrier into the epidermal and dermal layers of the skin, thereby allowing for the dermal administration of a glycosaminoglycan, such as hyaluronan, without requiring an injection. Through their ability to deliver hyaluronan to the epidermal and dermal layers, the present formulations are therefore suitable for use in dermal rejuvenation, enhancement, hyaluronan replenishment and protection therapy. The glycosaminoglycan compositions are also useful as delivery devices to facilitate the dermal and transdermal delivery of cosmetically and pharmaceutically active substances, including pharmaceuticals, polypeptides, proteins and similarly sized biomacromolecules, through the skin barrier. | 03-07-2013 |
| 20130065814 | INDUCTIVE PRODUCTION OF PLURIPOTENT STEM CELLS USING SYNTHETIC TRANSCRIPTION FACTORS - The present invention relates to use of synthetic factors in reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages. Specifically, the present application relates to fusion proteins containing proteins encoded by cell totipotency-related genes and transcription regulatory domains, their coding sequences, expression vectors, and compositions. The present application also relates to methods for reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages, and cells containing the fusion proteins or the coding sequences. | 03-14-2013 |
| 20130065815 | Fn 14/TRAIL Fusion Proteins - Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer. | 03-14-2013 |
| 20130072420 | BIOSYNTHETIC PROLINE/ALANINE RANDOM COIL POLYPEPTIDES AND THEIR USES - The present invention relates to a biosynthetic random coil polypeptide or a biosynthetic random coil polypeptide segment or biosynthetic conjugate, wherein said biosynthetic random coil polypeptide, said biosynthetic random coil polypeptide segment or said biosynthetic conjugate comprises an amino acid sequence consisting solely of proline and alanine amino acid residues, wherein said amino acid sequence consists of at least about 50 proline (Pro) and alanine (Ala) amino acid residues. Said at least about 50 proline (Pro) and alanine (Ala) amino acid residues may be (a) constituent(s) of a heterologous polypeptide or an heterologous polypeptide construct. Also uses and methods of use of these biosynthetic random coil polypeptides or polypeptide segments or said conjugates are described. | 03-21-2013 |
| 20130079271 | REVERSED BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS - In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 03-28-2013 |
| 20130079272 | METHODS OF PURIFYING POLYPEPTIDES - The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material. | 03-28-2013 |
| 20130085095 | PROTEIN COMPLEMENTATION REGULATORS - The present invention relates to protein complementation regulators and methods for reducing target-independent interaction of protein complementation molecules. | 04-04-2013 |
| 20130102521 | COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics. | 04-25-2013 |
| 20130116165 | LIGHT-ACTIVATED FUSION PROTEINS AND USES THEREFOR - The invention, in some aspects relates to synthetic, light-activated fusion proteins and their encoding polynucleotide molecules. In some aspects the invention additionally includes expression of the light-activated fusion proteins in cells and their use in methods such as therapeutic methods and candidate compound screening methods. | 05-09-2013 |
| 20130116166 | BIOMARKERS FOR IDIOPATHIC PULMONARY FIBROSIS - Biomarkers, kits, and diagnostic and treatment methods for idiopathic pulmonary fibrosis are provided. | 05-09-2013 |
| 20130130965 | METHOD TO DETECT AND TREAT INFECTIOUS OR INFLAMMATORY DIARRHEA BASED ON REG1 - The present invention relates to methods for the diagnosis, treatment and prevention of infectious and/or inflammatory diarrhea. | 05-23-2013 |
| 20130130966 | METHOD OF DETERMINING THE METASTATIC POTENTIAL OF A TUMOR - The present invention relates to the field of tumor biology. It provides a method for determining the risk of metastasis of a tumor, in particular, the risk of hematogenous dissemination and/or homing/survival in bone marrow, wherein the expression of RAI2, and optionally of other genes, in a tumor sample obtained from the patient is determined. The invention further provides a kit for determining the expression of RAI2 and/or other genes. A pharmaceutical composition comprising RAI2 in gene or protein form is disclosed, in particular for preventing and/or treating metastasis of a tumor. | 05-23-2013 |
| 20130137627 | METHODS AND KITS FOR IDENTIFYING A PREMATURE INFANT AT RISK OF HAVING OR DEVELOPING BRONCHOPULMONARY DYSPLASIA - The invention relates to methods and kits of identifying a premature infant at risk of having or developing bronchopulmonary dysplasia. More particularly, the present invention relates to a method of identifying a premature infant having or at risk of developing bronchopulmonary dysplasia, said method comprising detecting in a sample obtained from said premature infant at least one polymorphism in the SPOCK2 gene and/or its associated promoter, wherein the presence of said polymorphism indicates an increased risk of having or developing bronchopulmonary dysplasia. | 05-30-2013 |
| 20130143790 | HIGHLY-PURIFIED SOLUBLE THROMBOMODULIN AND METHOD FOR PRODUCING SAME - Highly-purified soluble thrombomodulin which has a content of host cell-originated proteins being in a ratio of less than 10 ng of the proteins per 10,000 U of the soluble thrombomodulin, wherein the soluble thrombomodulin is produced by a transformant cell obtained by transfecting a host cell with a DNA containing a nucleotide sequence encoding the soluble thrombomodulin. | 06-06-2013 |
| 20130157925 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I | 06-20-2013 |
| 20130157926 | BORONATED POLYMERS - The present invention relates to a boronated polymer according to Formula (1): a process for making the boronated polymer according to Formula (1), drug 10 delivery systems, aggregates, nanoparticles and hydrogels comprising the boronated polymer according to Formula (1). | 06-20-2013 |
| 20130157927 | CYSTEINE CROSS-LINKED STRUCTURAL PEPTIDES - Compositions and methods are provided using fusion peptides comprising at least one multi-functional solubility tag having an effective number of cross-linkable cysteines residues. The multi-functional peptidic solubility tags facilitate efficient fusion peptide production, easier downstream processing of the fusion peptide, and provide functional surface properties when coupled to a target material while the cross-linkable cysteines provide enhanced durability when binding the fusion peptide to a target material. | 06-20-2013 |
| 20130172229 | SYSTEMS AND METHODS OF DELIVERY OF BIOACTIVE AGENTS USING BACTERIAL TOXIN-DERIVED TRANSPORT SEQUENCES - The field of the present invention relates, in part, to a strategy for novel pharmaceutical applications. More specifically, the present invention relates to a genetically detoxified form of | 07-04-2013 |
| 20130178410 | METHODS FOR MODULATING SLOW MYOSIN - The present invention provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. The present invention also provides a method for modulating an expression level of a gene encoding slow myosin in a subject in need thereof, comprising administering to said subject a pharmaceutically effective amount of an expression vector comprising a gene encoding a nuclear receptor interaction protein (NRIP) and a pharmaceutically acceptable carrier. In a preferred embodiment, the expression vector is an adenoviral vector. | 07-11-2013 |
| 20130178411 | THERAPEUTIC AGENTS COMPRISING ELASTIC PEPTIDES - The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability. | 07-11-2013 |
| 20130190221 | MONOMERIC RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS - The present invention provides, in particular embodiments, for modified recombinant T cell receptor (TCR) ligands (RTLs) comprising a MHC class I or MHC class II component. The modified RTLs have redesigned surface features that preclude or reduce aggregation, wherein the modified molecules retain the ability to bind Ag-peptides, target antigen-specific T cells, inhibit T cell proliferation in an Ag-specific manner and have utility to treat, inter alia, autoimmune disease and other conditions mediated by antigen-specific T cells in vivo. | 07-25-2013 |
| 20130190222 | CONCENTRATED AQUEOUS SILK FIBROIN SOLUTION AND USE THEREOF - The present invention provides for concentrated aqueous silk fibroin solutions and an all-aqueous mode for preparation of concentrated aqueous fibroin solutions that avoids the use of organic solvents, direct additives, or harsh chemicals. The invention further provides for the use of these solutions in production of materials, e.g., fibers, films, foams, meshes, scaffolds and hydrogels. | 07-25-2013 |
| 20130196896 | CAR PEPTIDE FOR HOMING, DIAGNOSIS & TARGETED THERAPY FOR PULMONARY AND FIBROTIC DISORDERS - Disclosed are compositions and methods useful for delivering targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to effect a beneficial therapeutic result. The disclosed targeting is useful for delivering therapeutic and detectable agents to diseased tissue in an animal. | 08-01-2013 |
| 20130203645 | METHOD OF ENHANCING MUSCLE PROTEIN SYNTHESIS - The present invention relates to a method of enhancing muscle protein synthesis following physical exertion comprising administering to a human a composition comprising protein or essential amino acids and carbohydrates 30 minutes or less prior to, during, or within 30 minutes of running repeated sprints. Further, the invention relates to a program for enhancing muscle adaptation resulting from repeated sprints training. | 08-08-2013 |
| 20130203646 | SUPPORTING ACTIVITIES OF DAILY LIVING - The invention provides a method for supporting operational activities in daily living by providing a combination of (a) long-chain polyunsaturated fatty acids, particularly DHA and/or EPA, and (b) nucleosides or nucleotides, particularly uridine or its equivalent. The operational activities comprise eating; walking; toileting; bathing; grooming; dressing; use of communication equipment; making conversations; keeping appointments; use of household appliances; cleaning dishes; preparation of meal or drink; writing; reading; independent housekeeping; transportation and shopping. | 08-08-2013 |
| 20130210698 | MATERIALS AND METHODS FOR SUPPRESSING INFLAMATORY AND NEUROPATHIC PAIN - N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2′,3′-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.2 function suppressed inflammatory and neuropathic nociception, providing a method for treating pain and inflammation. | 08-15-2013 |
| 20130210699 | Methods and Compositions for Diagnosing and Treating Cervical Intraepithelial Neoplasia and Cervical Cancer - Disclosed herein are methods and compositions for diagnosing and treating diseases associated with a loss of cystatin E/M expression including cervical intraepithelial neoplasia and cervical cancer. Genetic mutations and exonic deletions which result in a loss of cystatin E/M expression are also disclosed. | 08-15-2013 |
| 20130217612 | COMPLETE GENOME SEQUENCE OF THE METHANOGEN METHANOBREVIBACTER RUMINANTIUM - The present invention includes the complete genome sequence for the methanogen, | 08-22-2013 |
| 20130217613 | DPY-30 Binding Peptides - Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to RSP3 or Ash2L and that bind to Dpy-30. | 08-22-2013 |
| 20130217614 | PRODUCTION OF PROTEIN SOLUTIONS FROM SOY - Soy protein products which can be reconstituted to provide an aqueous acidic solution having a preferred level of clarity are produced by extracting a soy protein source with an aqueous calcium chloride solution to cause solubilization of soy protein from the protein source and separating the resulting aqueous soy protein solution from residual soy protein source. Either, within about 20 minutes of separation step, the aqueous soy protein solution is diluted to a conductivity of less than about 90 mS and the pH of the aqueous soy protein solution is adjusted to about 1.5 to about 4.4 to produce an acidified soy protein solution having an absorbance of visible light at 600 nm (A600) of less than about 0.055, or, within about 40 minutes of the separation step, the aqueous soy protein solution is diluted to a conductivity of less than about 90 mS, the pH of the aqueous soy protein solution is adjusted to about 1.5 to about 4.4, the acidified soy protein solution is heat treated at a temperature of about 70° to about 160° C. for about 10 seconds to about 60 minutes to produce an acidified soy protein solution having an absorbance of visible light at 600 nm (A600) of less than about 0.055. The resulting acidified soy protein solution may be directly dried or further processed by concentration and diafiltration. Each of the steps of the process preferably is effected at a temperature of about 50° to about 60° C. | 08-22-2013 |
| 20130217615 | COMBINATION TREATMENT OF MAJOR DEPRESSIVE DISORDER - A method is provided for treating depression, and particularly major depression,by administering an effective amount of an SSRI medication that is augmented by administering an effective amount of an amphetamine prodrug, such as lisdexamfetamine, to patients receiving an SSRI medication. In particular, the amphetamine prodrug is administered to augment the effects of an SSRI medication in patients who respond poorly to the effects of the SSRI medication. | 08-22-2013 |
| 20130225476 | NOVEL BIOPOLYMER HAVING EXCELLENT TENSILE STRENGTH, EXTENSIBILITY AND TOUGHNESS - The present invention relates to a biopolymer having excellent tensile strength, extensibility and toughness. The present invention further relates to a nucleic acid molecule encoding the biopolymer of the invention, a vector comprising the nucleic acid molecule of the invention and a non-human host transformed with the vector of the invention. Furthermore, the present invention relates to methods for producing a biopolymer of the invention and to foams, films, gels, coatings, particles, capsules, springs or nonwoven mats as well as fibres comprising or consisting of the biopolymer of the invention. The present invention also relates to a method of producing fibres and the biopolymer of the invention for use in medicine, agriculture, cosmetics as well as surface, paper, leather and/or textile processing. | 08-29-2013 |
| 20130244924 | PEPTIDE COMPOUNDS TO REGULATE THE COMPLEMENT SYSTEM - The disclosure provides peptide compounds that regulate the complement system and methods of using these compounds. Specifically the disclosure provides an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The peptide compounds disclosed include peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and/or substitutions, deletions and/or substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The disclosure further provides pharmaceutical compositions comprising therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage. | 09-19-2013 |
| 20130244925 | MOLECULES MIMICKING AN AUTOANTIBODY IDIOTYPE AND COMPOSITIONS CONTAINING SAME - Specific peptides have been discovered that mimic an idiotype of an autoantibody. Such peptides may be formed into polymers. The peptides may be used in pharmaceutical compositions for the treatment of an autoimmune disease together with a pharmaceutically acceptable excipient. | 09-19-2013 |
| 20130252876 | COMPOSITIONS AND METHOD FOR PROMOTING MUSCULOSKELETAL REPAIR - A method of treating a musculoskeletal injury in a subject includes administering directly to a site of the musculoskeletal injury or to an area proximate the musculoskeletal injury an amount of SDF-1, MCP-3, or combinations thereof effective to promote repair of the musculoskeletal injury of the subject and recruit connective tissue progenitor cells to the site of the musculoskeletal injury. | 09-26-2013 |
| 20130252877 | METHOD FOR PREPARING ACTIVE PEPTIDES FROM CORN GERM PROTEINS - The present invention discloses a method for producing antihypertensive active peptides with corn germ protein as the material. The method comprises an alkali-heat treatment and continuous enzymolysis of the corn germ protein. The components with molecular weight less than 1000 Da in the active peptides obtained according to the present method account for more than 92%, and alanine-tyrosine (Ala-Tyr, AY) as the characteristic peptide fragments in the antihypertensive peptides accounts for more than 0.6%, so that the active peptides have a good ACE inhibitory activity in vitro as well as stability against temperature, pH and major gastrointestinal digestive enzymes, and have a significant effect of lowering blood pressure on spontaneous hypertension rats in vivo. The active peptides can be applied as a new functional nutrient to development and production of food, health food and pharmaceutical. | 09-26-2013 |
| 20130261045 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE - The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with β-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits α-secretase activity. The subject invention also provides methods to increase α-secretase expression and/or activity in cells by administering polyphenol flavonoids like (−)-epigallocatechin- | 10-03-2013 |
| 20130261046 | Container Closure Delivery System - The present invention relates to a container closure delivery system that is suitable for lyophilized pharmaceutical injectable powder products. The system comprises storage stable powder formulations and a container closure assembly design wherein the formulation can be filled and lyophilized with a standard fill finish equipment, and the formulations and lyophilization processes are optimized to produce a powder that readily dissolves upon contact with a diluent, thereby facilitating the direct injection of the lyophilized product without the need for a separate reconstitution/mixing/priming step. | 10-03-2013 |
| 20130267455 | CROSSLINKED PEPTIDE HYDROGELS - The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and/or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention. | 10-10-2013 |
| 20130267456 | THERAPEUTIC APPLICATIONS OF SMAD7 - The invention provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to mucositis. | 10-10-2013 |
| 20130274171 | TREFOIL FACTORS (TFF) FOR THE TREATMENT OF CHRONIC PULMONARY DISEASES - The present invention provides methods for enhancing or inducing airway epithelial repair and/or regeneration and/or for the normalization of airway epithelial remodeling, using local deposition of one or more pro-regenerative factors, preferably a peptide or protein from the trefoil family factor (TFF) family. The pro-regenerative factor is administered to a patient as a treatment of Chronic obstructive pulmonary disease (COPD), chronic bronchitis, Cystic fibrosis, Asthma, Bronchiectasis, Panbronchiolitis, pneumonia, ventilator associated pneumonia (VAP), hospital acquired pneumonia (HAP), community acquired pneumonia (CAP), severe community acquired pneumonia (sCAP) and | 10-17-2013 |
| 20130281355 | CELL CULTURE COMPOSITIONS AND METHODS FOR POLYPEPTIDE PRODUCTION - Cell culture media, such as chemically defined cell culture media, are provided, as are methods of using the media for cell growth (i.e., cell culture) and polypeptide (e.g., antibody) production. Compositions comprising polypeptides produced by the methods are also provided. | 10-24-2013 |
| 20130288948 | ESTABLISHMENT OF MOTIF COMPRISING ACIDIC AMINO ACID, CAPABLE OF STABILIZING PROTEIN IN CELLS, AND APPLICABLE TO PROTEIN THERAPY, CONTROL OF DIFFERENTIATION/UNDIFFERENTIATION OF CELL AND ANTIBODY THERAPY - A motif is searched which can inhibit the proteolysis of a protein that has been administered to a cell or an individual. Thus, disclosed is a method for designing/producing a protein having resistance to proteolysis. Specifically disclosed is a motif capable of inhibiting proteolysis, which comprises an amino acid region lying between the 396 | 10-31-2013 |
| 20130296221 | IMPROVED CAPPING MODULES FOR DESIGNED ANKYRIN REPEAT PROTEINS - Improved N-terminal capping modules for designed ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases. | 11-07-2013 |
| 20130296222 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN THERAPY - The present invention relates to a novel bacterial strain isolated and characterized from groundwater. The invention also relates to bacterial extracts and to the therapeutic use of same, notably in the context of the treatment of inflammations. | 11-07-2013 |
| 20130310302 | PROTECTIVE HYDROCOLLOID FOR ACTIVE INGREDIENTS - Partially deamidated rice endosperm protein or rice endosperm protein which is partially conjugated with mono-, di-, oligo- or polysaccharides is used as novel protective hydrocolloid for fat-soluble active ingredients and/or fat-soluble colorants. The present invention further includes compositions comprising that rice endosperm protein and at least one fat-soluble active ingredient/colorant, as well as their manufacture, that rice endosperm protein itself and its manufacture. These compositions are used for the enrichment, fortification and/or coloration of food, beverages, animal feed, personal care or pharmaceutical compositions. The present invention is directed to theses uses and to food, beverages, animal feed, personal care and pharmaceutical compositions containing such a rice endosperm protein and such a composition, respectively. | 11-21-2013 |
| 20130310303 | GLYCOGEN SYNTHASE KINASE-3 INHIBITORS - Novel peptide inhibitors of GSK-3, compositions containing same and uses thereof are disclosed. The novel peptide inhibitors are substrate-competitive inhibitors and have an amino acid sequence designed so as to bind to a defined binding site subunit in GSK-3. Also disclosed are GSK-3 substrate competitive inhibitors which bind to the defined binding site subunit in the enzyme. Also disclosed are mutants of GSK-3 and uses thereof for identifying a putative GSK-3 substrate competitive inhibitor. | 11-21-2013 |
| 20130324457 | 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF - Provided are 1-aryl-5-alkyl pyrazole compounds, of formula (I): | 12-05-2013 |
| 20130331309 | DISABLING AUTOPHAGY AS A TREATMENT FOR LYSOSOMAL STORAGE DISEASES - Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT). | 12-12-2013 |
| 20130345113 | Method of Use of Activated Functional Proteins to Improve Animal Health - It was found that feeding a composition including activated growth factor(s) increases feed to gain ratio, increases overall weight gain, reduces necessary antibiotic or electrolyte therapy and reduces mortality in animals. The composition is derived by first separating growth factor(s) from a source such as whey or blood, then subjecting the factor to an activation process, and then providing the activated growth factor to the animal. A feed additive comprising activated growth factors in appropriate amounts, shows results that are an improvement over standard therapies of supplementation. Application of activated growth factors may be by topical, injection or oral application. | 12-26-2013 |
| 20130345114 | Agent for Treating Allergic or Hypersensitivity Condition - The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition. | 12-26-2013 |
| 20140011727 | Methods of Evaluating Peptide Mixtures - The presently disclosed subject matter provides methods for evaluating and characterizing peptides, peptide mixtures, and polypeptide mixtures. More particularly, the presently disclosed subject matter provides methods for evaluating or characterizing complex peptide or polypeptide mixtures comprising glutamic acid, alanine, tyrosine, and lysine, e.g., Copolymer-1 or glatiramer acetate, including, but not limited to, methods of identifying. isolating, quantifying, and purifying amino acids, peptides, polypeptides, and combinations thereof having a diethylamide group instead of a carboxyl group present on the C-terminus. The presently disclosed methods can be used to determine the mole percent of polypeptides having a diethylamide group at a C-terminus thereof and can be used to evaluate one or more properties of a sample of one polypeptide mixture as compared to one or more properties of a different sample of a polypeptide mixture. | 01-09-2014 |
| 20140011728 | LONG-ACTING IL-1 RECEPTOR ANTAGONISTS - The present invention relates to IL-1 receptor antagonist compounds, compositions and use thereof as well as methods for preparation thereof. | 01-09-2014 |
| 20140011729 | METHODS OF AND COMPOSITIONS FOR INHIBITING THE PROLIFERATION OF MAMMALIAN CELLS - A method of preventing, inhibiting and/or reversing cell motility, actin filament assembly or disassembly, proliferation, colonization, differentiation, accumulation and/or development of abnormal cells in a subject is disclosed. The method is effected by administering to the subject a therapeutically effective amount of a ribonuclease of the T2 family having actin binding activity. | 01-09-2014 |
| 20140031274 | BIOLOGICAL ACTIVITY OF PLACENTAL PROTEIN 13 - The present invention relates to the biological and pharmacological effects of placental protein 13 (PP-13), an effect that may be used as a treatment and/or prevention of preeclampsia and placental insufficiencies, in pregnant female mammals, especially pregnant women. The invention relates to a method to treat female mammals with the purpose to precondition the uterine arteries and prevent and/or reverse the pathological conditions associated with placental insufficiency such as preeclampsia, HELLP and/or eclampsia. | 01-30-2014 |
| 20140038879 | SURFACE INDUCED DISASSEMBLY OF NANO CONTAINERS - The invention discloses composition of oxidized conducting polymer and micelle assembly for site specific delivery of guest molecule. This delivery is achieved by by polyvalent interaction between micelle assemblies and delocalized charges of polymer to trigger the disassembly. The invention further discloses the process of preparation of composition of oxidized conducting polymer and micelle assembly for site specific delivery of guest molecule. | 02-06-2014 |
| 20140045740 | ANALYSIS OF GLATIRAMER ACETATE - The present disclosure relates to methods for assessing molecular weight characteristics of glatiramer acetate using SEC-MALS. | 02-13-2014 |
| 20140066359 | METHODS FOR RECOVERING PEPTIDES/AMINO ACIDS AND OIL/FAT FROM ONE OR MORE ... - According to a first aspect, hydrolysis of a protein-containing raw material and separation of amino acids/peptides is carried out, wherein the hydrolysis is effected by using the endogenous enzymes of the protein-containing raw material. The hydrolysate is passed through a membrane filter, wherein peptide/amino acids follow a permeate stream, whilst the active enzymes continuously break down any protein residues that are deposited on the membrane surface. The enzymes are passed together with retentate back to the hydrolysis. Furthermore, an amino acid and peptide product and an oil product are described and the use thereof is disclosed. | 03-06-2014 |
| 20140094399 | BIODEGRADABLE POLY(BETA-AMINO ESTERS) AND USES THEREOF - Poly(β-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly(amine) nature of these polymers, they are particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings. | 04-03-2014 |
| 20140107012 | TREHALULOSE-CONTAINING COMPOSITION, ITS PREPARATION AND USE - A trehalulose-containing composition, its preparation and use. | 04-17-2014 |
| 20140113853 | Transducible Polypeptides for Modifying Metabolism - Methods and compositions for modifying the metabolism of a subject are provided. One embodiment provides a recombinant polypeptide having a polynucleotide-binding domain, a protein transduction domain, and a targeting domain. In a preferred embodiment, the polynucleotide-binding domain includes one or more HMG box domains. | 04-24-2014 |
| 20140135254 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS - Described herein are conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, which can be used, for example, in the treatment of a disorder such as cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of making the conjugates (e.g., therapeutic peptide-polymer conjugates and protein-polymer conjugates) and particles, methods of storing the particles and methods of analyzing the particles. | 05-15-2014 |
| 20140135255 | PEPTIDOMIMETIC MACROCYCLES - The present invention provides biologically active crosslinked polypeptides with improved properties relative to their corresponding precursor polypeptides, having good cell penetration properties and reduced binding to human proteins. The invention additionally provides methods of identifying and making such improved polypeptides. | 05-15-2014 |
| 20140135256 | TREATMENT OF EXTRACELLULAR MATRIX TO REDUCE INFLAMMATION - Pharmaceutical compositions are provided. The compositions comprise a compound comprising the hyaluronan-containing structure A-(low molecular weight hyaluronan domain)-B. The compositions also comprise a pharmaceutically acceptable excipient. A is hydrogen, a substituent that does not comprise a binding site for tumor necrosis factor stimulated gene-6 (“TSG-6”) protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. B is hydroxyl, a substituent that does not comprise a binding site for TSG-6 protein, a substituent that interferes with binding of TSG-6 protein immediately adjacent thereto, or chondroitin. The composition is suitable for administration by injection, inhalation, topical rub, or ingestion. Also disclosed are methods and kits for treating a site of inflammation in an individual in need thereof and for decreasing heavy chain modification of pathological hyaluronan at a site of inflammation in an individual in need thereof based on administering the compounds or the compositions. | 05-15-2014 |
| 20140135257 | USE OF A NUCLEOTIDE FOR IMPROVING THE HEAT STABILITY OF AN AQUEOUS MICELLAR CASEIN COMPOSITION - The invention relates to the use of one or more nucleotides for improving the heat stability of an aqueous micellar casein composition comprising 6 to 20 g per 100 ml of micellar casein, and having a pH of about 6 to 8. The invention also relates to heat-treated liquid nutritional compositions comprising 6 to 20 g, preferably 9-20 g, of protein per 100 ml of the composition and having a pH of about 6 to 8, in which all or a major part of said protein comprises micellar casein, further comprising one or more nucleotides. | 05-15-2014 |
| 20140155313 | HYDROGELS WITH COVALENTLY LINKED POLYPEPTIDES - The present invention provides methods of synthesizing hydrogels that contain covalently linked polypeptides. These polypeptides may be tetravalent peptides or polypeptides that bind to cell surface receptors. The hydrogels synthesized by the methods of the present invention may be used in wound dressings or applied directly to wounds to promote healing. | 06-05-2014 |
| 20140162933 | Methods and Compositions for Diagnosing, Prognosing, and Treating Neurological Conditions - This document provides methods and materials related to genetic variations of neurological disorders. For example, this document provides methods for using such genetic variations to assess susceptibility of developing Parkinson's disease. | 06-12-2014 |
| 20140162934 | NOVEL LIPIDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS - The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery. | 06-12-2014 |
| 20140171356 | CHEMICALLY IMMOBILIZED WNT PROTEIN AND METHODS OF USE - Methods are provided for contacting a target cell with a biologically active Wnt polypeptide that is coupled to a magnetic particle, for producing biologically active bead-coupled Wnt stimulator and Wnt inhibitor polypeptides, and for enriching a target cell population for Wnt responsive or DKK responsive cells. Compositions and kits for practicing the methods of the invention are also included, and generally include a biologically active Wnt stimulator polypeptide that is coupled to a magnetic particle. Compositions and kits may also include (i) a buffer that is substantially free of detergent, and/or (ii) a biologically active bead-coupled DKK polypeptide. | 06-19-2014 |
| 20140194340 | DIAGNOSING, MONITORING AND TREATING INFLAMMATION - The present invention provides methods and compositions for treating chronic inflammatory disease in a subject and associated pharmaceutical compositions, medical devices and systems. | 07-10-2014 |
| 20140194341 | Silica Compositions - Compositions are provided, the compositions comprising: a silica compound containing at least one nitrogen atom; and a carboxylated polymer containing at least one nitrogen atom. The compositions may be useful to control algal growth, including harmful algal blooms (HAB). | 07-10-2014 |
| 20140206596 | Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions - The present invention discloses a design for a molecular delivery vehicle capable of delivering a molecular payload to a target cell and its intracellular compartments. Also disclosed are highly pH-sensitive nanoconstruct that takes advantage of the requirement of cationic charge for internalization of CPPs to mask the non-specific internalization, compositions containing nanoconstruct, and methods for forming the same. | 07-24-2014 |
| 20140213501 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF - The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods. | 07-31-2014 |
| 20140213502 | CHEMICAL MODIFICATION OF APOLIPOPROTEIN MIMETIC PEPTIDES FOR THE PRODUCTION OF THERAPEUTIC AGENTS - Hydrocarbon stapling of apolipoprotein mimetic peptides increases the helicity of the peptides, enhances their ability to promote cholesterol efflux by multiple mechanisms and makes them resistant to proteolysis. Hydrocarbon stapled amphipathic helical peptides are useful in the treatment of cardiovascular diseases and other disorders. | 07-31-2014 |
| 20140213503 | SOLID COMPOSITION - The present invention provides a solid composition comprising the following ingredients (A) and (B):
| 07-31-2014 |
| 20140221270 | Methoxypolyethyleneglycol succinimidyl propionate modified recombinant ganoderma immunoregulatory protein, preparing method and application thereof - Methoxypolyethyleneglycol succinimidyl propionate modified recombinant | 08-07-2014 |
| 20140235526 | Methods for Generating Cardiomyocytes - The present disclosure provides method of generating cardiomyocytes from post-natal fibroblasts. The present disclosure further provides cells and compositions for use in generating cardiomyocytes. | 08-21-2014 |
| 20140249071 | ENHANCED ANABOLIC CYTOKINE PRODUCTION AND DELIVERY SYSTEM - Techniques and devices for removing (filtering out) unwanted/inhibitory components (for example, products, byproducts and/or cell output such as inhibitory catabolic proteins) from a composition (for example, autologous fluid or serum) containing such unwanted/inhibitory components. The devices include at least one construct designed to contain a composition (for example, autologous fluid or serum) containing inhibitory/unwanted components (products, byproducts and/or output of cells such as inhibitory catabolic proteins). The construct is provided with interior walls including specific protein capturing means designed to remove the inhibitory/unwanted component(s) (for example, specific protein(s)) from the composition. Proteins targeted for capture include, but are not limited to, catabolic cytokines such as IL-1β, IL-α, IL-6, TNFα, IFNγ and MMPS as these proteins inhibit the healing process. | 09-04-2014 |
| 20140274872 | COMPOSITIONS AND TREATMENTS BASED ON CADHERIN MODULATION - Anti-cadherin and anti-ZO-1 agents and compositions, and kits containing them for use in the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications. | 09-18-2014 |
| 20140274873 | COMPOSITION OF A SUSTAINED-RELEASE DELIVERY AND METHOD OF STABILIZING PROTEINS DURING FABRICATION PROCESS - As described herein, controlled and sustained administration of a therapeutic agent, such as a protein through the administration of one or more microparticles, may improve treatment of conditions, such as undesirable ocular conditions. The microspheres can be formulated to provide a sustained release of a protein, while reducing the number of protein aggregates, achieving desirable release profiles, and increasing stability of the protein within the microsphere formulations. | 09-18-2014 |
| 20140296128 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS - The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity. | 10-02-2014 |
| 20140296129 | REGULATION OF RECEPTOR EXPRESSION THROUGH DELIVERY OF ARTIFICIAL TRANSCRIPTION FACTORS - The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively. | 10-02-2014 |
| 20140303067 | TREATMENT OF EOSINOPHILIC ESOPHAGITIS - The present invention provides a method for the treatment of eosinophilicesophagitis comprising administering non-digestible oligosaccharides. | 10-09-2014 |
| 20140315781 | METHODS OF TREATING FATTY LIVER DISEASE WITH HELMINTH-DERIVED GLYCAN-CONTAINING COMPOUNDS - The present invention provides a compound comprising a helminth-derived glycan and/or glycoconjugate thereof (e.g., a compound comprising a Lewis | 10-23-2014 |
| 20140315782 | METHODS AND PRODUCTS FOR INCREASING FRATAXIN LEVELS AND USES THEREOF - Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom. | 10-23-2014 |
| 20140342975 | Therapeutic Process For The Treatment Of The Metabolic Syndrome And Associated Metabolic Disorders - The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens. | 11-20-2014 |
| 20140371130 | USE OF A HOLOTOXIN TO REDUCE ENDOPLASMIC RETICULUM-ASSOCIATED DEGRADATION OF MISFOLDED PROTEINS - The present invention provides a method of blocking endoplasmic reticulum associated degradation of functional but misfolded proteins. | 12-18-2014 |
| 20140371131 | ADHESIVE BIOPOLYMERS AND USES THEREOF - Provided herein are polymers having the general formula I as defined herein, | 12-18-2014 |
| 20140371132 | CODON SIGNATURE FOR NEUROMYELITIS OPTICA - The present invention provides for the diagnosis and prediction of neuromyelitis optica (NMO) in subject utilizing a unique a codon signature in B cells that has now been associated with NMO and not with any other autoimmune disease. More particularly, the method may comprise the steps of (a) providing a 10 B-cell containing sample from a subject, or DNA or RNA isolated therefrom; (b) determining the VH1 and/or VH4 structure of VH1NH4-expressing B-cells from said subject, (c) determining the mutational frequency VH1 and/or VH4 genes; (d) identifying the presence or absence of a codon signature associated with NMO or risk of NMO; and (e) selecting patients exhibiting said codon signature. | 12-18-2014 |
| 20140378370 | LOW VISCOSITY HIGHLY CONCENTRATED SUSPENSIONS - The present invent ion also provides a high concentration low viscosity suspension of an pharmaceutically acceptable solvent with one or more sub-micron or micron-sized non-crystalline particles comprising one or more proteins or peptides. Optionally one or more additives in the pharmaceutically acceptable solvent to form a high concentration low viscosity suspension with a concentration of at least 20 mg/ml and a solution viscosity of between 2 and 100 centipoise that is suspendable upon shaking or agitation, wherein upon delivery the one or more sub-micron or micron-sized peptides dissolves and do not form peptide aggregates syringeable through a 21 to 27-gauge needle. | 12-25-2014 |
| 20150038400 | Compositions, the Preparation and Use Thereof - The present teachings provide new compositions comprising polycations and polycations, and the preparation and use of these new compositions. In one aspect, the new compositions are complex coacervates. The compositions described herein can have several desired properties, including, low interfacial tension in water, adjustable cohesive strength, antimicrobial activity, suitability for dissolution at or near physiological pH, biocompatiblility, and/or biodegradability. The compositions can have the ability of promoting cell attachment, cell adhesion, cell migration, cell differentiation, and/or morphogenesis. Thus, in various embodiments, the complex coacervates can be used in water-based applications, for example, in the body. | 02-05-2015 |
| 20150072918 | PROTEIN PURIFICATION - A method for purifying a polypeptide by ion exchange chromatography is described in which a gradient wash is used to resolve a polypeptide of interest from one or more contaminants. | 03-12-2015 |
| 20150072919 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 03-12-2015 |
| 20150111812 | POLYSACCHARIDE-BASED HYDROGELS AND HYBRID HYDROGELS AND PRECURSORS THEREOF, METHODS OF MAKING SAME, AND USES THEREOF - Hydrogels and hybrid hydrogels, methods of making the hydrogels/hybrid hydrogels, and methods of using the hydrogels/hybrid hydrogels. The hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties). The hybrid hydrogels have polysaccharide moieties (e.g., chitosan or hyaluronic acid moieties) and poly(ester amide) moieties. The poly(ester amide) moieties can have one or more arginine moieties. The hydrogels/hybrid hydrogels can be used, for example, in consumer products and as cargo carrier materials (e.g., as therapeutic agent carriers). | 04-23-2015 |
| 20150119315 | MODULATION OF ESTROGEN RECEPTOR-RELATED RECEPTOR GAMMA (ERR GAMMA) AND USES THEREFOR - This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERRγ activity to the subject. Such agents can include one or more ERRγ agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair). | 04-30-2015 |
| 20150141320 | COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene. | 05-21-2015 |
| 20150148283 | NOVEL CASEIN PROTEIN PRODUCT - The present invention relates to a process for producing a casein protein product comprising the steps of:—providing a casein concentrate starting material,—heat-treating the material,—cooling the heat-treated material,—subjecting the cooled material to a treatment with a crosslinking enzyme,—optionally subjecting the cooled material to a treatment with a coagulant and—processing the material into the casein protein product/allowing the casein protein product to form. | 05-28-2015 |
| 20150290284 | IDEOTYPICALLY MODULATED PHARMACOEFFECTORS FOR SELECTIVE CELL TREATMENT - In a method embodiment, a method includes introducing a plurality of Ideotypically Modulated Pharmacoeffectors (IMP) into a population of cells. Each IMP may include a detection domain and an activation domain. One or more epitopes is bound by the detection domain. The activation domain is activated in response to the binding. Applications may include but are not limited to viral infections, other intracellular infections, cancers, vector-borne diseases, autoimmune diseases, cellular diseases, cellular enhancement, and research. | 10-15-2015 |
| 20150290356 | Solution Blow Spun Polymer Fibers, Polymer Blends Therefor and Methods of Use Thereof - Compositions comprising biomedical polymers, and in particular unique blends of poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) are provided. Methods of forming polymer fibers using such compositions and solution blow spinning techniques are also provided, as well as methods of delivering the blow spun polymer fibers onto a surface (e.g., such as tissue for use as a surgical scaffold, sealant or tissue adhesive). | 10-15-2015 |
| 20150314018 | METHOD FOR CELLULAR RNA EXPRESSION - The present invention relates to expressing RNA in cells and, in particular, enhancing viability of cells in which RNA is to be expressed. Specifically, the present invention provides methods for expressing RNA in cells comprising the steps of preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells. Thus, preventing engagement of IFN receptor by extracellular IFN and inhibiting intracellular IFN signalling in the cells allows repetitive transfer of RNA into the cells. | 11-05-2015 |
| 20150343090 | INTRACELLULAR DELIVERY SYSTEM AND METHODS - This disclosure describes, in one aspect, a composition for intracellular delivery of a polypeptide. Generally, the composition includes a substrate that has a surface, a cleavable linker affixed to at least a portion of the surface, and a cargo polypeptide bound to the cleavable linker. In some embodiments, the cargo polypeptide can further include a targeting peptide. In another aspect, this disclosure describes a method for intracellular delivery of a polypeptide. Generally, the method includes administering to a subject any embodiments of the composition summarized above, and cleaving the cleavable linker, thereby releasing the cargo polypeptide from the substrate. | 12-03-2015 |
| 20150352071 | METHODS FOR REDUCING MUSCLE SORENESS AFTER EXERCISE USING BETA-HYDROXY-BETA-METHYLBUTYRATE - Nutritional compositions containing beta-hydroxy-beta-methylbutyrate (HMB) are administered to an individual to reduce muscle soreness after exercise. The compositions contain a source of HMB; a protein source with at least about 21% branched-chain amino acids, by weight of total protein in the protein source; and a carbohydrate blend which contains a combination of rapid release and sustained release carbohydrates. | 12-10-2015 |
| 20150353614 | Synthetic Transcription Factor and Uses Thereof - The present invention provides for a synthetic transcription factor (TF) comprising a first peptide capable of binding a target ligand, a second peptide capable of binding a target DNA, and a peptide linker linking the first and second peptides. The present invention also provide for a system for modulating the mutagenesis frequency of a host cell. The host cell has a mutator rate (R) which is inversely proportional to a phenotypic trait (P). | 12-10-2015 |
| 20150374780 | COMPOSITIONS AND METHODS TO PREVENT CANCER WITH CUPREDOXINS - The present invention relates to compositions comprising peptides that may be variants, derivatives and structural equivalents of cupredoxins that inhibit the development of premalignant lesions in mammalian cells, tissues and animals. Specifically, these compositions may comprise azurin from | 12-31-2015 |
| 20150374833 | POLYPEPTIDE HYDROGEL AND METHOD FOR PRODUCING SAME - A polypeptide hydrogel of the present invention is a hydrogel of a polypeptide derived from spider silk proteins, and has a moisture content of 85.0 to 99.9 mass % based on 100 mass % of the polypeptide hydrogel. A method for producing the hydrogel includes: a solution production step in which a polypeptide derived from spider silk proteins is dissolved in at least one dissolving solvent selected from the group consisting of: (A) dimethyl sulfoxide; (B) dimethyl sulfoxide with an inorganic salt; and (C) N, N-dimethylformamide with an inorganic salt, so as to obtain a solution of the polypeptide; and a substitution step in which the solution produced in the solution production step is substituted with a water-soluble solvent. Thus, the present invention provides a polypeptide hydrogel having excellent water retentivity and a polypeptide hydrogel suitable for application to a living body. | 12-31-2015 |
| 20160015812 | COMBINATION OF A LIGHT RAY WITH A CYTOCHROME C OXIDASE SUBSTRATE PARTICULARLY FOR IMPROVING THE APPEARANCE OF THE SKIN AND/OR HAIR - The present invention relates more specifically to a cosmetic treatment method intended in particular to improve the appearance of the skin and/or hair comprising the simultaneous and/or sequential administration: | 01-21-2016 |
| 20160045563 | MUSCLE-ATROPHY-PREVENTING AGENT - A muscle atrophy-preventing agent includes a milk-derived basic protein fraction and/or a decomposed product of the milk-derived basic protein fraction as an active ingredient. The muscle atrophy-preventing agent is remarkably effective in preventing muscle mass decline and increasing muscle mass, and thus is useful in preventing and treating various muscle diseases, such as sarcopenia and disuse muscle atrophy. | 02-18-2016 |
| 20160046682 | ARTIFICIAL TRANSCRIPTION FACTORS ENGINEERED TO OVERCOME ENDOSOMAL ENTRAPMENT - The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a gene promoter, engineered to overcome endosomal entrapment after transduction into cells. Such artificial transcription factor comprises a polydactyl zinc finger protein fused to an inhibitory or activatory protein domain, a nuclear localization sequence, a protein transduction domain, and an endosome-specific protease-recognition site. These transducible artificial transcription factors are particularly useful for the treatment of diseases caused or modulated by membrane-bound receptor proteins, nuclear receptor proteins or products of haploinsufficient genes. | 02-18-2016 |
| 20160058822 | RADIOPAQUE INJECTABLE NUCLEUS HYDROGEL COMPOSITIONS - A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising:
| 03-03-2016 |
| 20160101031 | Methods of Regulating Skin Health and Appearance with a Combination of Flavonoid and Vitamin B3 - The disclosure relates to topical compositions comprising a flavonoid compound and a vitamin B | 04-14-2016 |
| 20160101072 | Therapeutic uses of enzyme inhibitors - The invention relates to use of compounds which inhibit VAP-1/SSAO activity for the treatment of muscular dystrophy. The invention also relates to combined preparations comprising compounds which inhibit VAP-1/SSAO activity, and their use for the treatment of muscular dystrophy. | 04-14-2016 |
| 20160114055 | POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS - The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. | 04-28-2016 |
| 20160130607 | AGENTS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS - New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes. | 05-12-2016 |
| 20160137718 | Stabilized Receptor Polypeptides and Uses Thereof - The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided. | 05-19-2016 |
| 20160145533 | METHOD FOR EXTRACTING ORGANIC SOLIDS AND OIL FROM MARINE ORGANISMS ENRICHED WITH ASTAXANTHIN - A method is for extracting shrimp oil. Particularly, shrimp processing water (EPC) is recovered and subjected to a dissolved air flotation (DAF) system after adding a flocculating agent. The suspended and dissolved solids form aggregates that are recovered from the surface by a procedure referred to as “skimming”. The skimming product is then directed into a horizontal centrifuge (decanter) in order to separate the solid phase (SOC) and the liquid phase having water and shrimp oil. The liquid phase is pumped into the 3-phase vertical centrifuge in order to separate the shrimp oil, the water, and the solids. The solids recovered after using the separator can then be added to the solid phase obtained after settling. The resulting shrimp oil is very rich in astaxanthin and the resulting water contains very little organic material and can be returned to the general processing plant effluent. | 05-26-2016 |
| 20160151497 | pH SENSITIVE CARRIER AND PREPARATION METHOD THEREOF, AND pH SENSITIVE DRUG AND pH SENSITIVE DRUG COMPOSITION EACH CONTAINING THE CARRIER, AND METHOD FOR TREATING OR PREVENTING DISEASES USING THE SAME | 06-02-2016 |
| 20160158242 | Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins - The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed. | 06-09-2016 |
| 20160158716 | NOVEL RECONSTITUTION ASSEMBLY - The present invention relates to the provision of novel centrifuge activated assembly that can be used for reconstitution of dry formulations on addition of diluent and to pharmaceutical or veterinary products suitable for parenteral administration that have been prepared with or in the devices according to the novel method of the invention. | 06-09-2016 |
| 20160175260 | PROTEASE ASSISTED NATIVE-PROTEIN DELIVERY APPROACH (PANDA) | 06-23-2016 |
| 20160184251 | CRYSTALLINE POLYMORPHIC FORMS OF MONOSODIUM N-[-8-(2-HYDROXYBENZOYL)AMINO]CAPRYLATE - The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino]caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-VI). The present invention also provides an amorphous form of SNAC. | 06-30-2016 |
| 20160185824 | BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING - There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a β-sheet tape-like substructure wherein the material comprises a pair of self assembling complementary polypeptides. | 06-30-2016 |
| 20160186192 | GENE EXPRESSION TECHNIQUE - The present invention provides a method for producing a desired protein (such as a desired heterologous protein) comprising:
| 06-30-2016 |
| 20160193150 | REDUCING OR NON-REDUCING POLYNUCLEOTIDE POLYMER FOR DRUG DELIVERY AND METHOD FOR PREPARING SAME | 07-07-2016 |
| 20160201067 | Composition for Enhancing Transgene Expression in Eukaryotic Cells and Method for Enhancing Production of a Target Protein Encoded by a Transgene | 07-14-2016 |
| 20160250169 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | 09-01-2016 |
| 20180021283 | APPLICATION OF CHLOROGENIC ACID IN PREPARING MEDICINES FOR TREATING LUPUS ERYTHEMATOSUS | 01-25-2018 |
| 20180024116 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | 01-25-2018 |
| 20180024117 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | 01-25-2018 |
| 20180024118 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | 01-25-2018 |
| 20180024119 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | 01-25-2018 |
| 20180024120 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | 01-25-2018 |
| 20190144935 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING NEUROLOGICAL CONDITIONS | 05-16-2019 |
| 20110263500 | Curcumin Conjugates for Treating and Preventing Cancers - Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the LHRH receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma. LH-Curcumin conjugates may be used against cancer cells that express the LH receptor: prostate, breast, ovary, testis, uterus, pancreas, and melanoma. | 10-27-2011 |
| 20110306547 | LHRH - ANTAGONISTS IN THE TREATMENT OF FERTILITY DISORDERS - A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural level S thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist/day . LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralising the negative effects of HCG. | 12-15-2011 |
| 20130029911 | ALBUMIN FUSION PROTEINS - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 01-31-2013 |
| 20130116177 | USE OF AROMATASE INHIBITORS FOR SYNCHRONIZING OVULATION, INDUCING SUPEROVULATION OR DOUBLE OVULATION AND IMPROVING TWINNING AND FERTILITY IN A MAMMAL - Described herein are methods for synchronizing ovulation in a herd, inducing superovulation in a single animal, and improving frequency of successful implantation and development of fertilized ova. | 05-09-2013 |
| 20140155327 | Process for the Synchronization of Ovulation for Timed Breeding Without Heat Detection - A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred without heat detection at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy. | 06-05-2014 |
| 20160106853 | CURCUMIN CONJUGATES FOR TREATING AND PREVENTING CANCERS - Conjugating LHRH to curcumin (LHRH- | 04-21-2016 |
